Meng-Wan Zhang
Yun-Jie Shen
Jian-Guang Yu- Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China
Cardiovascular diseases, involving vasculopathy, cardiac dysfunction, or circulatory disturbance, have become the major cause of death globally and brought heavy social burdens. The complexity and diversity of the pathogenic factors add difficulties to diagnosis and treatment, as well as lead to poor prognosis of these diseases. MicroRNAs are short non-coding RNAs to modulate gene expression through directly binding to the 3′-untranslated regions of mRNAs of target genes and thereby to downregulate the protein levels post-transcriptionally. The multiple regulatory effects of microRNAs have been investigated extensively in cardiovascular diseases. MiR-223-3p, expressed in multiple cells such as macrophages, platelets, hepatocytes, and cardiomyocytes to modulate their cellular activities through targeting a variety of genes, is involved in the pathological progression of many cardiovascular diseases. It participates in regulation of several crucial signaling pathways such as phosphatidylinositol 3-kinase/protein kinase B, insulin-like growth factor 1, nuclear factor kappa B, mitogen-activated protein kinase, NOD-like receptor family pyrin domain containing 3 inflammasome, and ribosomal protein S6 kinase B1/hypoxia inducible factor 1 α pathways to affect cell proliferation, migration, apoptosis, hypertrophy, and polarization, as well as electrophysiology, resulting in dysfunction of cardiovascular system. Here, in this review, we will discuss the role of miR-223-3p in cardiovascular diseases, involving its verified targets, influenced signaling pathways, and regulation of cell function. In addition, the potential of miR-223-3p as therapeutic target and biomarker for diagnosis and prediction of cardiovascular diseases will be further discussed, providing clues for clinicians.
Introduction
Cardiovascular diseases (CVDs), as the first leading cause of death from non-communicable diseases worldwide, include atherosclerosis, coronary artery disease, heart failure, hypertension, arrhythmia, etc (1–3). Deaths from CVDs are increasing in recent years, mainly resulting from the global aging and population growth (2–5). The driving causes of cardiovascular system dysfunction refer to multiple factors such as aging, hyperlipidemia or atherosclerosis, hypertension, inflammatory response or infection, and genetic influence. Although medical advances in diagnosis and treatments of CVDs, as well as methods to improve prognosis of these diseases, have made benefits for patients, the burden of CVDs remains huge in all regions of the world, as one of the vital obstacles of sustainable development of human (2, 3, 6). Current techniques and drugs to treat CVDs are still limited and the diagnostic methods are often complex and invasive, therefore convenient and effective biomarkers and therapeutic targets for CVDs are urgently needed.
MicroRNAs (miRNAs/miRs), as a kind of non-coding RNA, have been proved to participate in multiple cardiovascular disorders and varieties of pathological processes of CVDs, such as atherosclerosis, coronary artery disease, heart failure, cardiac hypertrophy, cardiac remodeling, arrhythmia, and myocardium ischemia (7–10). For example, miR-208, which is cardiac-specifically expressed, is the first miRNA to be found affecting cardiac hypertrophy. MiRNAs have been increasingly recognized as the potential therapeutic target for CVDs and the miRNA-based therapeutic approaches to perform in clinical applications are challenging but promising (11). MiRNAs are synthesized firstly in the nucleus through transcribing the genes from DNA to primary miRNAs and then processing them to precursor miRNAs (12–15). The precursor miRNAs, which are transferred from nucleus to cytoplasm, are cleaved to become the mature miRNAs duplex (16). In most cases, one of two strands (5p/3p) of mature miRNAs duplex are degraded or less active and is called the passenger strand, while the reserved strand is often identified as the guide strand to form miRNA-induced silencing complex and executes the active regulatory function, although sometimes the passenger strand is also functional (17–19). The canonical mechanisms underlying the post-transcriptional gene silencing by miRNAs are directly binding to the 3′-untranslated regions of the target mRNAs, which lead to the degradation of mRNAs and the reduction of protein levels (20, 21). Besides intracellular gene regulation, miRNAs can be also transported by microparticles, exosomes, or binding to proteins in body fluids, as well as in the free form in blood, to play a part in intercellular signaling (20, 22–24). These diverse and powerful functions of miRNAs lay the foundation for their potential use in clinical diagnosis and treatments of many diseases such as CVDs.
MiR-223-3p is recognized as the guide strand of the miR-223 duplex and used to be called miR-223 (25). Although the other strand named miR-223-5p or miR-223* has been recognized functional in some cases recently (26, 27), most studies have been focused on the regulatory effects of miR-223-3p. MiR-223-3p is initially thought to be a myeloid-specific miRNA affecting hematopoiesis, immune response, and inflammatory diseases (28–31), but currently has been reported to express in many other types of cells such as hepatocytes and cardiomyocytes (32, 33). It has been demonstrated that miR-223-3p is related to multiple pathological processes or features of CVDs including atherosclerosis, vascular or myocardium remodeling, abnormal platelet reactivity, and myocardium ischemia (33–37), which draws our attention to the potential role of miR-223-3p in the diagnosis and treatments of CVDs. In this review, we will systemically elaborate the role of miR-223-3p in different pathophysiological activities causing CVDs and highlight the function of miR-223-3p as therapeutic target, as well as diagnostic or predictive biomarker in these diseases.
MiR-223-3p in Lipid Metabolism Dysfunction and Atherosclerosis
Lipid metabolism dysfunction, represented by disturbed triglyceride and cholesterol homeostasis, as well as abnormal level and function of lipoproteins, may lead to severe lipid-associated diseases, including atherosclerosis, non-alcoholic fatty liver disease, and diabetes. Atherosclerosis is thought to be a driving force for coronary artery disease and ischemic cerebral stroke, mediated by complex mechanisms including lipid metabolism disorder, vascular cellular dysfunction, chronic inflammation, and plaque development (8). Cholesterol biosynthesis, transport, and efflux are essential for maintaining systemic lipid homeostasis and a high level of plasma cholesterol has been considered a risk factor for atherosclerosis development (38). Lipoproteins, especially the atheroprotective high-density lipoproteins (HDLs) and the atherogenic low-density lipoproteins, carry on different roles in cholesterol metabolism and atherosclerosis (39, 40). MiR-223-3p has been involved in modulating cholesterol homeostasis and transport function of lipoproteins and also has been proved to regulate cellular activities contributing to the pathogenesis of atherosclerosis.
Effect of MiR-223-3p on Lipoprotein Function and Cholesterol Metabolism
Lipoproteins can combine with nucleic acids to form complex and transport nucleic acids systemically or specifically (41–43). HDLs are responsible for reversing the transport of cholesterol from periphery back to liver and finally excreting cholesterol out of the body (39). As an important member of lipoproteins especially in atherosclerosis, HDLs are capable of delivering endogenous miRNAs including miR-223-3p to neighbor cells for intercellular communication and cellular target genes regulation, and this delivery ability may present differently in pathological situations such as hypercholesterolemia (24, 44, 45). MiR-223-3p was demonstrated as one of the most abundant plasma HDL-miRNAs in familial hypercholesterolemia patients or atherosclerotic mice, and also quite abundant in HDLs of healthy subjects (24). HDL-carried miR-223-3p which generated from polymorphonuclear neutrophils (PMNs) and macrophages was upregulated by native HDLs through increasing the expression of Dicer, and the export of miR-223-3p from PMNs and macrophages to HDLs was increased by HDLs and PMNs activation through promoting the activity of protein kinase C (PKC) and production of reactive oxygen species (ROS) (45). Excessive dietary intake of trans-fatty acids, as one of the risk factors of CVDs, also has been reported to have an impact on HDL-carried miR-223-3p through affecting the plasma HDL-C levels and inflammatory markers (44).
Both native and reconstituted HDLs are capable of acquiring endogenous or exogenous miR-223-3p and delivering it to recipient cells including hepatic and endothelial cells through combination with scavenger receptor class B type I (SR-BI) (24, 46). SR-BI, which is found expressed in hepatocytes, endothelial cells or macrophages, is the primary and high-affinity HDL receptor, and thus plays an important role in regulating cholesterol homeostasis (47, 48). There is an interaction between SR-BI and miR-223-3p. It was demonstrated that SR-BI could facilitate the selective uptake of HDL-cholesterol (HDL-C) and HDL-carried miR-223-3p by cells, as well as might affect miR-223-3p levels in PMNs and macrophages (45), while miR-223-3p, in turn, decreased the expression of SR-BI in hepatocytes, resulting in reduced HDL-C uptake (32, 49). Besides, miR-223-3p also regulates other proteins involved in cholesterol metabolism to reduce cholesterol biosynthesis and promote cholesterol efflux.
MiR-223-3p is abundant in human liver and primary hepatocytes (50). Hepatic miR-223-3p is either delivered from plasma into the liver or natively expressed in hepatocytes. The abundance and functional activity of miR-223-3p increased with elevation of cholesterol levels in hepatocytes and circulation (32). Hepatic miR-223-3p decreased the mRNA and protein level of SR-BI through directly targeting the binding sites of 3′-untranslated region in SR-BI mRNA of human while inhibition of endogenous miR-223-3p abrogated these effects, proving that SR-BI was a downstream target of miR-223-3p in human. This posttranscriptional regulation of SR-BI markedly reduced the uptake of HDL-C and lipid accumulation in hepatic cells (32, 49). The similar regulatory effects of miR-223-3p on SR-BI were also found in human coronary arterial endothelial cells, suggesting the endothelial protection by miR-223-3p. In addition to SR-BI, two cholesterol biosynthetic enzymes 3-hydroxy-3-methylglutaryl-CoA synthase 1 (HMGCS1) and methylsterol monooxygenase 1 (SC4MOL) were found to be direct targets of miR-223-3p, resulting in cholesterol biosynthesis repression by miR-223-3p. Moreover, miR-223-3p also increased efflux of cholesterol by upregulating ATP-binding cassette transporter A1 (ABCA1) through directly targeting transcription factor Sp3 (32). Thus, the reduced uptake of HDL-C and biosynthesis of cholesterol, as well as the promoted efflux of cholesterol, are likely to decrease the liver cholesterol levels. These regulatory mechanisms involved in human cholesterol metabolism by miR-223-3p imply that miR-223-3p may influence plasma lipid levels and lipid-related diseases such as hypercholesterolemia or atherosclerosis in a diverse manner. Based on the experiments conducted in miR-223(-3p/5p) knockout mice, the depletion of miR-223(-3p/5p) contributed to hypercholesterolemia and the elevation of plasma cholesterol levels were associated with HDL-C. However, the elevated HDL-C levels caused by miR-223(-3p/5p) deficiency were thought to be the results of different regulation of target genes in rodents such as SR-BI, which was found inhibited in miR-223(-3p/5p) deficient mice (32). Therefore, the role of miR-223-3p on plasma lipid levels and lipid-related diseases in human still needs further researches.
Taken together, miR-223-3p modulates cholesterol metabolism through directly or indirectly targeting genes related to cholesterol transport, biosynthesis, and efflux (Figure 1). Both HDL-carried miR-223-3p and hepatocyte-expressed miR-223-3p could execute the regulatory function. MiR-223-3p could inhibit the expression of SR-BI, while the inhibition could lead to reduced uptake of HDL-carried miR-223-3p from plasma, so this loop regulation may be one of the mechanisms helping to maintain the cholesterol homeostasis in cellular or systemic level.
Figure 1. MiR-223-3p is involved in cholesterol transport, biosynthesis, and efflux. Both endogenous and exogenous miR-223-3p in hepatocytes contribute to maintaining cholesterol homeostasis through targeting multiple genes related to cholesterol transport, biosynthesis, and efflux. Exogenous miR-223-3p is mostly originated from PMNs or macrophages and transported by HDLs. The uptake of HDL-carried miR-223-3p depends on SR-BI which is identified as one of the targets of miR-223-3p. Other targets involved in cholesterol metabolism include HMGCS1, SC4MOL and Sp3. MiR-223-3p directly inhibits the expression of these proteins to reduce the cholesterol uptake and biosynthesis, as well as to increase the cholesterol efflux. MiR-223-3p levels in hepatocytes can be upregulated with the elevation of cellular or circulating cholesterol.
Effect of MiR-223-3p on Vascular Cells, Platelets, and Macrophages
Vascular endothelial cells (VECs) and vascular smooth muscle cells (VSMCs), as well as platelets and macrophages, are involved in all stages of atherosclerosis and play vital roles in plaque development (8). Endothelial dysfunction contributes to cellular inflammatory phenotypes through activating multiple signaling pathways and increasing the excretion of pro-inflammatory factors, consequently prompting monocytes recruitment and differentiation into macrophages which could form inflammatory foam cells in the lesions of vessel walls (51, 52). Aberrant proliferation, differentiation, and migration of VSMCs promote atherosclerosis progression through the formation of neointima and plaque (53). MiR-223-3p is firstly described in hematopoietic cells and blood cells and recent studies have shown that miR-223-3p is a pleiotropic miRNA in several tissues (28, 34). Although some studies consider that miR-223-3p may be barely expressed in VECs or VSMCs, a considerable amount of miR-223-3p which probably derived and excreted from platelets, monocytes, or macrophages has been found in these two types of cells, executing anti-inflammatory and anti-atherosclerotic effects (35, 46, 54). In addition, miR-223-3p impacts atherosclerosis also via regulating cytopoiesis, cell survival, and the function of platelets and macrophages (55–57).
VECs can ingest HDL-carried miR-223-3p or miR-223-3p from activated-platelet-derived exosomes in plasma (46, 54). Platelet activation displays pro-atherosclerotic effects, resulting from its role in endothelial damages and thrombus formation, however, activated-platelet-derived exosomes are found to be protective for atherosclerosis and endothelial inflammation (54, 58). The components contained in activated-platelet-derived exosomes included a high level of miR-223-3p, which was found upregulated in exosomes of atherosclerotic models (54). MiR-223-3p ingested by VECs contributed to the downregulation of intercellular adhesion molecule 1 (ICAM1), which could be upregulated by tumor necrosis factor α (TNF-α) or thrombosis (46, 54). Given that miR-223-3p was thought to be barely expressed in VECs and mostly from extracellular sources, it indicates that extracellular miR-223-3p is capable of regulating gene expression in cells. MiR-223-3p can suppress the inflammation and endothelial activation through directly or indirectly regulating ICAM1 in VECs. MiR-223-3p downregulated the expression of ICAM1 through directly targeting or depending on the suppression of nuclear factor kappa B (NFκB) and mitogen-activated protein kinase (MAPK) signaling pathways, with inhibiting cytoplasm-to-nucleus translocation of NFκB p65 and phosphorylation of p38, c-Jun N-terminal kinase (JNK), and extracellular signal-regulated kinase (ERK) (46, 54). MiR-223-3p could also be transcribed and secreted from platelets and leukocytes to serum, and then entered VSMCs and vascular walls, resulting in elevation of miR-223-3p levels in serum and vascular walls of atherosclerotic animals and patients. MiR-223-3p reduced VSMCs proliferation and migration, as well as increased cell apoptosis, through directly targeting insulin-like growth factor 1 receptor (IGF1R) to inhibit its downstream phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway with reduced phosphorylation of AKT. The regulation on these signaling pathways affected cellular activities of VSMCs, and ultimately suppressed vascular neointimal formation and atherosclerosis (35). Although these findings have been argued by other studies of miR-223-3p on VSMCs function, which indicated that overexpression of miR-223-3p promoted the proliferation and migration of VSMCs (59) and thus downregulation of miR-223-3p might decrease neointimal hyperplasia and prevent restenosis after angioplasty through augmenting expression of genes implicated in VSMCs differentiation and contractility (60), it is quite evident that miR-223-3p can help to prevent pathological changes in atherosclerosis.
Platelets and macrophages play vital roles in the development of plaque and thrombosis during the atherosclerotic progression. As one of the most abundant miRNAs in platelets (61–63), miR-223-3p showed a mild acceleration on platelets production but with no influence on platelets function (55). It suggests that platelet function may not depend on regulation pathways mediated by miR-223-3p. Contrast to effects on platelets, miR-223-3p plays significant roles in macrophages differentiation, survival, and function during inflammatory stimulation and atherosclerosis. As the same as activated platelets, macrophages generate microvesicles containing miRNAs (64). Although miR-223-3p contained in activated macrophage-derived microvesicles could be transported to monocytes and induce the differentiation from monocytes to macrophage, as well as macrophages survival, suggesting the pro-inflammatory effects of microvesicles containing miR-223-3p (56), the upregulation of miR-223-3p in macrophages presented protective effects against atherosclerosis through decreasing macrophage foam cells, macrophage-mediated lipid deposition, and excretion of pro-inflammatory factors. The anti-atherosclerotic effects of miR-223-3p in macrophages were performed through activating the PI3K/AKT pathway with upregulation of p-AKT to inhibit the toll-like receptor 4 (TLR4)/NFκB pathway with suppression of phosphor-p65. The expression of miR-223-3p was reduced in lipopolysaccharide-induced macrophages, while in lesions of atherosclerotic animals it was upregulated, probably in a feedback way (57).
To summarize, miR-223-3p can function as an endocrine genetic signal for intercellular communication among blood cells, immune cells, and vascular cells, mediated by HDLs, platelet-derived exosomes, or macrophage-derived microparticles. It also plays essential roles against atherosclerotic progression primarily through anti-inflammation, endothelial protection, reducing vascular remodeling, and decreasing lipid deposition (Figure 2), indicating its therapeutic role for atherosclerosis and related CVDs.
Figure 2. Anti-atherosclerotic role of miR-223-3p. MiR-223-3p plays important roles in atherosclerotic progression based on its effects on various types of cells involved in atherosclerosis including VECs, VSMCs, and macrophages. MiR-223-3p can suppress endothelial inflammation and activation through targeting ICAM1 and regulating NFκB and MAPK signaling pathways. MiR-223-3p also alleviates vascular remodeling mediated by proliferation and migration of VSMCs and lipid deposition and inflammation mediated by macrophages through PI3K/AKT or TLR4/NFκB signaling pathways. Besides, MiR-223-3p is an important endocrine signal factor for communication between platelets, monocytes, and vascular cells.
MiR-223-3p as a Potential Biomarker for Atherosclerosis
The characteristics of miRNAs, which can be easily acquired from plasma or serum in patients and conveniently detected by commonly used techniques, make it an important potential biomarker in multiple diseases (8, 65). Circulating levels of miR-223-3p have been associated with atherosclerotic diseases and hyperlipidemia (35, 66–68). It was found that miR-223-3p levels were elevated in serum and atherosclerotic vessels of patients with atherosclerosis, as well as atherosclerotic models established in apolipoprotein E deficient mice (35). Hypertension associated with hyperlipidemia, as the major risk factor leading to atherosclerotic diseases, could mimic the atherosclerotic situation and increase the plasma and platelet levels of miR-223-3p but reduced the levels in platelet-derived microvesicles in hamsters (68). However, other research indicated that plasma miR-223-3p levels were reduced in patients with abdominal aortic aneurysm, an atherosclerosis-related disease (66). The lower level of plasma miR-223-3p was correlated with increased atherosclerotic manifestations including coronary artery disease, peripheral arterial disease and stroke in heart failure patients, and elevated levels of atherosclerosis-related indicators such as growth differentiation factor 15, as well as augmented risk of cardiovascular-related rehospitalization (67). Thus, patients or animal models with only atherosclerosis or atherosclerotic situation seem to manifest a higher level of circulating miR-223-3p, while in patients combined with other diseases, atherosclerosis is associated with reduced circulating miR-223-3p. Although miR-223-3p has the potential to protect against atherosclerosis based on its regulation of lipid metabolism and cellular activities involved in atherosclerosis, its role to function as a biomarker of atherosclerosis diagnosis or risk prediction remains indeterminate. Further researches to investigate the explicit role of miR-223-3p as a diagnostic or prognostic biomarker for atherosclerosis and atherosclerosis-related diseases based on large cohorts and rigorous designs are needed.
MiR-223-3p in Coronary Artery Disease
Coronary artery disease is usually originated from atherosclerotic pathological alterations which lead to coronary artery narrow or block and ultimately ischemia of myocardium (69). Therefore, it is also known as coronary heart disease or ischemic heart disease, including multiple clinical manifestations such as stable angina pectoris and acute coronary syndrome (ACS), and affects lots of people worldwide (69, 70). There have been many researches uncovering the effects of miR-223-3p in coronary artery disease, mostly in regard to its adverse impacts on myocardial infarction and potential regulatory mechanisms involved in antiplatelet therapy, as well as its role in diagnosis and risk prediction of coronary artery disease.
MiR-223-3p in Myocardial Infarction
Myocardial infarction, as a main category of ACS, is a worldwide devastating coronary artery disease with high morbidity and mortality, usually caused by a severe reduction of blood flow to the cardiac tissues and the accompanying myocardial ischemia or hypoxia (7). Cardiac damages induced by these conditions are closely related to processes such as cardiomyocytes apoptosis, oxidative stress, and inflammation, so therapies to alleviate these processes, as well as angiogenic factors, are conducive to recover cardiac function (7, 71). Pathological conditions present during or after myocardial infarction include myocardial fibrosis, arrhythmia, and ischemic/reperfusion (I/R) injury, etc (7, 72–74). Some researches have indicated that miR-223-3p can protect cardiomyocytes from myocardial I/R-induced inflammation and necroptosis, while others have proved that miR-223-3p displays pro-apoptosis and anti-angiogenesis effects, as well as promotes myocardial fibrosis and arrhythmia induced by myocardial infarction.
I/R injury, commonly induced by interventional therapies such as percutaneous coronary intervention or thrombolytic therapy, which are necessary when myocardial infarction occurred, could result in cardiomyocytes apoptosis and necrosis and has been demonstrated to be manipulated by gene regulation (26, 75, 76). MiR-223-3p has been reported upregulated in I/R hearts and involved in mechanisms underlying I/R-induced cardiomyocytes necroptosis in myocardial infarction (26, 77). MiR-223-3p cooperative with miR-223-5p inhibited cell necroptosis involved in I/R-induced myocardium injuries through regulating inflammatory response and necrotic signaling pathway respectively, which together promoted the necroptosis (26, 78–80). MiR-223-3p could attenuate I/R-triggered inflammation through suppressing the NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome signaling pathway. MiR-223-3p directly targeted IkB kinase α (IKKα) and NLRP3 to abrogate the activation of NLRP3 inflammasome and downregulate the expression of TNF-α and interleukin 1 β (IL-1β), the inflammatory cytokines involved in I/R-triggered inflammation. While miR-223-5p repressed the necrotic signaling pathway through the inhibition of the necrosome containing receptor-interacting protein 3 (RIP3) with its partners receptor-interacting protein 1 (RIP1) and mixed lineage kinase domain-like (MLKL) (26). Taken together, miR-223-3p may exert beneficial effects on I/R-induced inflammatory response and cardiomyocytes necroptosis following myocardial infarction and other ischemic heart diseases.
Despite the protective effects on I/R-induced damages, more studies have regarded miR-223-3p as a potential therapeutic target that should be suppressed in myocardial infarction due to its effects of pro-apoptosis in cardiomyocytes and antiangiogenesis. Angiogenesis, which is normally restricted by the physiological activity of VECs, is essential for the recovery of myocardial ischemia and myocardial infarction. It was demonstrated that miR-223-3p was highly expressed in natively quiescent VECs which were freshly isolated from human vessels, while in VECs that were cultured for angiogenesis with stimulation of growth factors the miR-223-3p were downregulated to very low levels (81). This sharp downregulation of miR-223-3p is in accordance with previous studies that suggested nearly undetectable expression of miR-223-3p in cultured VECs and may result from the epigenetic silencing mechanisms or a lack of exogenous miR-223-3p delivered by other cells from plasma in vivo as we mentioned in the former parts (46, 54, 81). MiR-223-3p in VECs reduced cellular proliferation and migration to inhibit angiogenesis through targeting integrin β 1 (ITGB1). Downregulation of ITGB1 suppressed the phosphorylation of vascular endothelial growth factor receptor 2 (VEGFR2) and fibroblast growth factor receptor 1 (FGFR1) of growth factor (GF) signaling pathway, leading to inhibition of AKT signaling pathway, while the antagonist of miR-223-3p reversed these antiangiogenic effects (81). Another study revealed that miR-223-3p was upregulated in ischemia cardiac microvascular endothelial cells from a myocardial infarction model and also played antiangiogenic roles. MiR-223-3p inhibited endothelial cells proliferation and migration through targeting ribosomal protein S6 kinase B1 (RPS6KB1) to inhibit hypoxia inducible factor 1 α (HIF-1α) signaling pathway, an important pathway for angiogenesis, and affect the downstream proteins including vascular endothelial growth factor (VEGF), MAPK, PI3K, and AKT (37).
Furthermore, miR-223-3p was found to be concerned with the hypoxia-induced cardiomyocytes apoptosis. Hypoxia is a common condition during myocardial ischemia and acts as a promoting factor of apoptosis, contributing to ischemic heart diseases such as myocardial infarction (82, 83). It was proved that miR-223-3p in cultured cardiomyocytes was increased under 1% O2 hypoxia and directly suppressed Kruppel-like factor 15 (KLF15), a regulator of cardiomyocyte structure and function to repress cardiac hypertrophy, to promote hypoxia-induced apoptosis and oxidative stress of cardiomyocytes (82), although others reported that 10% O2 alveolar hypoxia induced reduction of miR-223-3p expression in ventricular myocardium of mice (84). Inhibition of miR-223-3p reduced hypoxia-induced cardiomyocytes apoptosis with the induction of anti-apoptotic protein B cell lymphoma 2 (BCL2) and reduction of pro-apoptotic protein B cell lymphoma 2-associated X (BAX), as well as decrease of cleaved caspase 3. Besides, inhibition of miR-223-3p also repressed the production of ROS and decreased peroxidation activities under hypoxia with reducing the malondialdehyde (MDA) contents and enhancing antioxidant enzymes such as superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase 1 (GPX1), to alleviate hypoxia-induced oxidative stress (82).
Myocardial fibrosis is a pathological change that could occur after myocardial infarction to obstruct the renewal of myocardium, mainly resulting from abnormal proliferation and differentiation of cardiac fibroblasts which take place of dead cardiomyocytes, and finally leads to myocardial remodeling and stiffness, as well as other complications related to myocardial infarction (85–88). MiR-223-3p has been shown to participate in fibrosis, including the cardiac fibrosis after myocardial infarction (85, 89). MiR-223-3p, which could be regulated by transforming growth factor β (TGF-β), was abundant in activated cardiac fibroblasts than cardiomyocytes and could stimulate cardiac fibroblasts proliferation, migration, differentiation, collagen synthesis, and α-smooth muscle actin (ACTA2) expression. The pro-fibrosis effects mediated by miR-223-3p were through targeting RAS p21 protein activator (RASA1), a RAS signal negative regulator, to upregulate the downstream MAPK and PI3K/AKT signaling pathways with increasing the phosphorylation of MAPK kinase 1/2 (MEK1/2), ERK1/2, and AKT, leading to myocardial fibrosis and deterioration of ventricular function (85).
Arrhythmia is another severe disorder following myocardial infarction and caused by electrophysiological dysfunction, especially characterized by extended action potential due to the reduction of transient outward K+ current (Ito) (90–92). MiR-223-3p was thought to have the potential to regulate potassium voltage-gated channel subfamily D member 2 (KCND2), a subunit of voltage-gated transient outward K+ channel carrying Ito, probably leading to a reduction of Ito (93). A recent study verified this and proved the role of miR-223-3p suppressing arrhythmia in myocardial infarction. In the ventricular cardiomyocytes of a myocardial infarction animal model, it was found that miR-223-3p levels were elevated, while expression of KCND2 and Ito were diminished resulting from the direct inhibition of KCND2 by miR-223-3p, and the upregulation of miR-223-3p promoted arrhythmia following myocardial infarction (94). Therefore, blocking the endogenous miR-223-3p is possible to develop into a therapeutic method for the prevention of myocardial fibrosis and arrhythmia after myocardial infarction or other ischemia situations, consequently improving the prognosis of these diseases.
Therefore, on the one hand, miR-223-3p may act as an inducer of myocardial infarction due to its promotion of hypoxia-induced cardiomyocytes apoptosis, antagonism to angiogenesis, and induction of complications following myocardial infarction including fibrosis and arrhythmia. On the other hand, miR-223-3p may improve I/R injury after myocardial infarction based on its inhibition of inflammatory response and necroptosis in cardiomyocytes (Figure 3). Although the expression of miR-223-3p was found increased in cardiomyocytes of myocardial infarction models and heart tissues of patients with myocardial infarction (94, 95), the study investigating the potential of circulating miR-223-3p as a biomarker related to myocardial infarction remains scarce.
Figure 3. Regulatory mechanisms of miR-223-3p in myocardial infarction. MiR-223-3p participates in different pathophysiological activities affecting myocardial infarction through regulation on multiple genes and diverse signaling pathways. MiR-223-3p promotes hypoxia-induced cardiomyocyte injury and inhibits the recovery of myocardial ischemia with its anti-angiogenesis effects during myocardial infarction. Myocardial fibrosis and arrhythmia can be induced by miR-223-3p to impact the prognosis of myocardial infarction. Besides, miR-223-3p is helpful for alleviation of I/R injury which often occurs after myocardial infarction.
MiR-223-3p as a Potential Biomarker and Therapeutic Target for Coronary Artery Disease
Although at present there exist some efficient medical interventions for the treatment of coronary artery disease such as percutaneous coronary intervention, clinical non-invasive biomarkers, which could accurately and conveniently be used for assisting diagnosis, assessing the severity, evaluating the efficacy of treatment, and predicting prognosis of coronary artery disease, are still in need. Based on the multiple functions of miR-223-3p associated with the pathophysiological processes of coronary artery disease, it is expected to become a biomarker for the disease.
Role of MiR-223-3p in Antiplatelet Therapy
Platelet activity contributes to the pathophysiological process in coronary artery disease, especially the formation of thrombosis (96). Antiplatelet therapy plays a significant role in pharmacological prevention of cardiovascular events and markedly impacts the prognosis of coronary artery disease, including the classic dual antiplatelet therapy (DAPT) with aspirin and clopidogrel, combination of aspirin and other P2Y12 antagonists, or monotherapy with one single antiplatelet drug (97). Responsiveness to the antiplatelet drugs and the platelet activity in patients with ischemic CVDs determine the benefits from antiplatelet therapy, while poor responsiveness or high platelet activity, known as high on-treatment platelet reactivity, is related to the risk of adverse cardiovascular outcomes (98–101). MiR-223-3p is quite abundant in both platelets and plasma, and directly targets P2Y12 in platelets, making it important for antiplatelet drugs, especially the P2Y12 antagonists used in antiplatelet therapy such as clopidogrel and ticagrelor (35, 62, 102, 103).
In patients with non-ST elevation ACS who received a regular DAPT with aspirin and clopidogrel, it was indicated that both the levels of miR-223-3p in plasma and platelets were downregulated in low clopidogrel response patients (104, 105), characterized by the high platelet reactivity index (PRI) of patients based on the measurement of vasodilator-stimulated phosphoprotein phosphorylation (106–108). MiR-223-3p levels were negatively correlated with PRI and the reduced miR-223-3p in plasma or platelets was demonstrated to be the only independent predictive factor of low responders to clopidogrel determined by PRI, compared with other factors that could potentially affect platelet reactivity, such as age, genotypes, use of calcium channel blockers or proton-pump inhibitors, and diabetes (104, 105). Therefore, low levels of circulating miR-223-3p may be a promising biomarker to predict the poor responsiveness to clopidogrel in ACS patients and the decrease of miR-223-3p in platelets is probably involved in the mechanism of clopidogrel resistance based on its inhibition of P2Y12 in platelets.
While downregulation of miR-223-3p might increase the platelet reactivity to reduce the efficacy of DAPT containing clopidogrel, the enhanced inhibition of platelet reactivity by more potent P2Y12 antagonists ticagrelor or prasugrel instead of clopidogrel of DAPT in patients with non-ST elevation ACS was associated with the elevation of plasma miR-223-3p (109). Therefore, miR-223-3p levels seem to be positively correlated with the effectiveness of antiplatelet therapy with P2Y12 antagonists. Besides, it was reported that in patients with ACS, plasma miR-223-3p level decreased 24 h after switching the DAPT from clopidogrel to ticagrelor in order to further inhibit platelet reactivity (96). Another study also showed that inhibition of platelet reactivity in healthy volunteers with prasugrel or DAPT containing prasugrel decreased the circulating miR-223-3p (62). In patients with coronary artery disease who received antiplatelet treatment for 24 h, the severity of coronary artery disease based on SYNTAX score was positively correlated with the platelet level of miR-223-3p, which might indirectly reflect the relation between platelet reactivity and miR-223-3p (110). Thus, although miR-223-3p can inhibit P2Y12 in platelets to affect the platelet reactivity, the circulating miR-223-3p levels may also be influenced by degree of P2Y12 inhibition and associated with platelet reactivity, and as a result, the definite correlation between circulating miR-223-3p levels and platelet reactivity might depend on status of patients, categories of drugs, or administration time. Even so, circulating miR-223-3p is helpful to predict the efficacy of antiplatelet therapy, especially the responsiveness to clopidogrel in ACS patients. Thus, circulating miR-223-3p may be useful for identifying patients suitable to receive clopidogrel as one of the antiplatelet drugs, thus saving the time and cost of switching therapeutic strategy for these patients.
Role of MiR-223-3p in Diagnosis, Severity Assessment, and Risk Prediction of Coronary Artery Disease
So far, the effective and convenient biomarker for coronary artery disease is still lacking. It was reported that in patients with coronary artery disease, the circulating miR-223-3p levels were elevated and positively associated with the severity of coronary atherosclerotic lesions evaluating by Gensini scores (111). The increased circulating miR-223-3p in coronary artery disease also could be used to predict cardiovascular death risk for patients, in particular for patients with ACS (112). Besides, compared with patients with stable coronary artery disease, the plasma HDL-carried miR-223-3p in ACS patients decreased during the transcoronary passage, indicating that in ACS patients the uptake of HDL-carried miR-223-3p by the coronary vascular wall was promoted, which suggested the positive correlation between uptake of plasma HDL-carried miR-223-3p and severity of coronary artery disease (113). Thus, miR-223-3p may probably be developed into a biomarker for assessing the severity and predicting the death risk of coronary artery disease. The levels of serum miR-223-3p were upregulated in myocardial infarction patients, compared with healthy controls and angina pectoris patients (114). While another study showed that circulating miR-223-3p levels were negatively correlated to the risk of myocardial infarction (102). More researches are needed to confirm the role of miR-223-3p as a diagnostic or predictive biomarker of myocardial infarction. Furthermore, the expression of miR-223-3p in peripheral blood mononuclear cells was downregulated in patients who were diagnosed as coronary artery disease with significant or insignificant stenosis compared with healthy controls, which was most prominent in patients with insignificant stenosis, indicating that miR-223-3p in peripheral blood mononuclear cells might be positively related to severity of coronary artery disease and could be used for discriminate patients with significant or insignificant stenosis (115).
Taken together, owing to the complex mechanisms and diverse symptoms of coronary artery disease, miR-223-3p may play multiple roles in these diseases, depending on its regulatory effects on the development of atherosclerosis, myocardial ischemia or hypoxia, and platelet function. The circulating miR-223-3p can be developed into both a therapeutic target and a biomarker to evaluate the treatment effects in coronary artery disease because it is capable of regulating the platelet aggregation and predicting the responsiveness to antiplatelet drugs of patients. MiR-223-3p is a promising biomarker that can be used for evaluating the severity of coronary artery disease such as stenotic degree of coronary atherosclerosis and predicting the prognosis of coronary artery disease, for its convenient detection, lower cost, and less damage to human body. Future studies should be more focused on the specific diagnostic or predictive function of miR-223-3p in coronary artery disease of different categories, or with different pathogenic mechanisms and inducing factors.
MiR-223-3p in Heart Failure
Heart failure is one of the most serious CVDs because of its high morbidity and mortality, mainly characterized by exhausted cardiac function of systole and diastole, and threatens worldwide people for a lack of effective treatments (116, 117). Cardiac hypertrophy, especially pathological cardiac hypertrophy, which acts as a cardiac compensatory mechanism in response to multiple pathophysiological stress, leads to cardiac ventricle remodeling and is an important pathogenic factor for heart failure (118). Other cardiac ventricle remodeling processes including fibrosis and malignant arrhythmia also contribute to the development of heart failure (119–121). Besides, pro-inflammatory conditions in myocardium that may result from systemic inflammation, such as activation and polarization of macrophages infiltrating into the myocardium, also promote heart failure progression (122, 123). Researchers have found numerous heart failure-related miRNAs such as miR-223-3p which prominently plays a part in heart failure through regulating cardiomyocytes hypertrophy and inflammation. In addition, miR-223-3p levels have been proved closely related to complications or combined symptoms of heart failure.
Effect of MiR-223-3p on Pathophysiological Processes in Heart Failure
Current researches have demonstrated that miR-223-3p has biphasic effects on heart failure through bidirectional regulation of cardiac hypertrophy and promotion of inflammatory response. Both in the rat model of cardiac hypertrophy induced by transverse aorta constriction and in hypertrophic cardiomyocyte models treated with different inducing reagents endothelin-1 or phenylephrine, the expression of miR-223-3p in myocardium and cardiomyocytes were downregulated (124, 125). The mechanism underlying the phenylephrine-induced downregulation of miR-223-3p in cardiomyocytes was suppressing glycogen synthase kinase 3 β activity to reduce β-catenin degradation and increase its activation (125). This modulation upregulated SRY-box transcription factor 2, which could promote cardiomyocytes proliferation and increase heart size, to inhibit the transcription of primary miR-223 (125, 126). Inhibition of primary miR-223 increased the stromal interaction molecule 1 (STIM1), a target of miR-223-3p, to induce cardiomyocyte hypertrophy through elevating the cytosolic Ca2+ levels of cardiomyocytes (125, 127–129). When overexpressing miR-223-3p or miR-223(-3p/5p) in cardiomyocytes, the hypertrophy was ameliorated mainly manifesting as smaller cellular surface area, downregulation of classic pathological hypertrophy marker genes encoding atrial natriuretic peptide (ANP), B type natriuretic peptide (BNP), α-actinin, and myosin heavy chain 6/7 (MYH6/7) (124, 125). The protective effects of miR-223-3p against cardiomyocytes hypertrophy might also depend on direct inhibition of troponin I3 interacting kinase (TNNI3K), a cardiac kinase that was upregulated in hypertrophic cardiomyocytes and induced cardiomyocytes hypertrophy through regulating cardiac remodeling process (124, 130, 131). Overexpression of miR-223-3p decreased the phosphorylation of cardiac troponin I, the downstream target of TNNI3K, and reversed the increased intracellular Ca2+ concentration and contractility of cardiomyocytes that were induced by TNNI3K, thus resulting in amelioration of cardiomyocytes hypertrophy (124). Notably, TNNI3K is also thought to be a promoter of physiological cardiac hypertrophy (132), so miR-223-3p may target TNNI3K to suppress either physiological or pathological cardiac hypertrophy.
Similar to the findings in models of cardiac hypertrophy, miR-223-3p was also downregulated in the myocardium of patients with non-end stage heart failure, more prominently in non-diabetic heart failure patients compared with diabetic heart failure patients or healthy controls (133). Among the advanced heart failure patients who received heart transplantation directly or after a period of left ventricular assist devices support, the expression of miR-223-3p in failing hearts before transplantation was significantly higher in patients with a period of left ventricular assist devices support and positively correlated with the cardiac index values, which reflect the cardiac output and function. This suggested that miR-223-3p might be involved in cardiac reverse remodeling and heart recovery (134). Therefore, miR-223-3p can be downregulated in models of cardiac hypertrophy or heart failure and might make a beneficial contribution to heart failure primarily through alleviating the ventricle remodeling processes concerned in cardiac hypertrophy, promoting the heart recovery process, and improving the cardiac function.
However, others have reported that overexpressed miR-223-3p could induce both pathological and physiological cardiac hypertrophy, as well as regulate the inflammatory response in hearts, probably resulting in the development of heart failure. MiR-223-3p was found upregulated in hearts of end stage heart failure patients and mouse models of cardiac hypertrophy induced by isoproterenol treatment or transverse aorta constriction (33, 135, 136), suggesting the detrimental roles of miR-223-3p in cardiac hypertrophy and heart failure, which was opposite to the above-mentioned studies (124, 125, 133). Both pathological and physiological cardiac hypertrophy have been found in transgenic mouse models with cardiac-specifically overexpression of miR-223(-3p/5p) (33, 137). These transgenic mice could develop pathological cardiac hypertrophy at the age of 8–12 weeks, characterized by higher heart/body weights, larger size of cardiomyocytes, interstitial fibrosis, upregulation of pathological cardiac hypertrophy marker genes in hearts, and impaired cardiac function which could lead to heart failure. Furthermore, in miR-223(-3p/5p) knockout mice, isoproterenol-induced pathological cardiac hypertrophy and heart failure were alleviated, also indicating the harmful role of miR-223(-3p/5p) in heart failure (33). MiR-223-3p directly targeted apoptosis repressor with CARD (ARC), which was reduced in human failing hearts and involved in cardiomyocytes hypertrophy and apoptosis, to induce pathological cardiac hypertrophy in animals and cardiomyocytes (33, 138, 139). Aiming to block the inductive effects of miR-223-3p for cardiac hypertrophy and heart failure, researchers screened a heart-related circular RNA to directly bind miR-223-3p and increase the expression of ARC of cardiomyocytes, resulting in alleviation of cardiac hypertrophy and heart failure induced by isoproterenol (33). This throws light on the development of the promising therapeutic target for heart failure.
The opposite effects of miR-223-3p in cardiac hypertrophy progression and heart failure may result from different stimuli and species to establish models of cardiac hypertrophy, considering different mechanisms of cardiac hypertrophy inducers such as endothelin-1, phenylephrine, or isoproterenol, and the species variation such as rats, mice, and human. The different expressions of miR-223-3p among patients may be due to diverse progression of disease such as non-end stage or end stage of heart failure. Besides, in experiments overexpressing miR-223-3p in vitro or in vivo, different regulatory effects on cardiac hypertrophy were observed, as in vitro studies showed inhibition on cardiac hypertrophy while in vivo studies showed induction on cardiac hypertrophy (33, 124, 125, 137). It is believed that in vivo studies are closer to real pathophysiological processes in cardiac hypertrophy and heart failure in human. Therefore, it is reasoned that miR-223-3p may display an inductive effect on cardiac hypertrophy and heart failure in human body, although more studies are needed.
Physiological cardiac hypertrophy is an adaptive response of hearts which is often caused by exercise training and characterized by relatively normal cardiac structure and function without fibrosis or abnormal expression of pathological cardiac hypertrophy gene markers such as ANP, BNP, and MYH7 (140, 141). Physiological cardiac hypertrophy was found in 3, 6, or 12-months aged transgenic mice overexpressing miR-223(-3p/5p), only manifesting larger hearts and thicker left ventricular walls with enhanced cardiac function (137). The inductive effects of miR-223(-3p/5p) on physiological cardiac hypertrophy were mediated by activation of the AKT signal pathway which played significant roles in the promotion of physiological cardiac hypertrophy (137, 142, 143). MiR-223-3p repressed the degradation of HIF-1α through directly inhibiting F-Box and WD repeat domain containing 7 (FBXW7) or targeting activin A receptor type 2A (ACVR2A) to downregulate egl-9 family hypoxia inducible factor 3 (EGLN3). The activated HIF-1α signaling pathway could increase phosphorylation of AKT directly or through upregulating periostin. Meanwhile, miR-223-3p in cardiomycytes was found to directly target two upstream positive regulators of AKT pathway, IGF1R and ITGB1, tending to inhibit the phosphorylation of AKT. Although both positive and negative regulators of AKT were influenced, the overexpression of miR-223(-3p/5p) led to the activation of AKT signaling pathway and induced physiological cardiac hypertrophy in models (137). Dual contribution of miR-223-3p overexpression to both pathological and physiological cardiac hypertrophy might result from the difference of transgenic models construction, as the length of DNA fragments containing primary miR-223 and the sequences of the primers used to generate transgenic models were different (33, 137), possibly leading to the diverse abundance of miR-223-3p overexpression and effects on cardiac hypertrophy.
In addition, miR-223-3p could also accelerate heart failure depending on its pro-inflammatory effects in macrophages including activation and polarization of macrophage toward a pro-inflammatory (M1) phenotype, as well as induction of inflammation markers and secretion of cytokines, probably contributing to the development of heart failure (122, 123, 144).
Conclusively, miR-223-3p regulates pathophysiological processes that drive heart failure, including hypertrophy of cardiomyocytes and myocardium, as well as the inflammatory response. Although the specific role of miR-223-3p in cardiac hypertrophy and heart failure remains controversial, the therapeutic method to repress miR-223-3p with a heart-related circular RNA and thus to alleviate cardiac hypertrophy and heart failure has been identified (33). Therefore, miR-223-3p seems to be a promising therapeutic target in clinical treatments of heart failure.
MiR-223-3p as a Potential Biomarker for Heart Failure
Circulating biomarkers can facilitate the diagnosis, therapy, and prognostic assessment of heart failure. Currently, the classic and recommended biomarkers for heart failure evaluation only refer to BNP or N terminal pro BNP (NT-proBNP) (145). However, BNP or NT-proBNP is not a specific biomarker for heart failure because some other diseases also display an elevation of BNP or NT-proBNP, such as cardiopulmonary disease and renal failure. Thus, to screen more effective and specific biomarkers for heart failure is still in need. Based on the stability and functional diversity, miRNAs could be potential and powerful biomarkers for heart failure (146, 147). The relationship between circulating miR-223-3p and heart failure has been investigated both in human and animal models.
There are evidences that in acute heart failure patients, plasma miR-223-3p decreased significantly compared with healthy controls or chronic heart failure patients, and its further decline was associated with the increased risk of 180-day mortality in these patients (148, 149). In addition, the plasma miR-223-3p level decreased 48 h after hospitalization, and its level was negatively correlated with circulating growth differentiation factor 15 that was identified as one of the parameters for worse clinical outcomes in acute heart failure. The correlation was more obvious in the severest group of patients, while not observed at the time of admission (150). The circulating levels of miR-223-3p in heart failure patients were also negatively related to rehospitalization caused by CVDs (67). Both atherosclerotic diseases and renal injuries are common in heart failure (67, 151). It was reported that in heart failure patients the reduced circulating miR-223-3p was associated with increased manifestations of atherosclerosis and elevation of atherosclerosis-related indicators (67). Circulating levels of miR-223-3p were also negatively associated with the tubular damage biomarker neutrophil gelatinase associated lipocalin, which could signify early worsening of renal function in heart failure (152–154). These concomitant situations often aggravate the severity of heart failure and lead to adverse prognosis in patients, so looking for biomarkers, including the candidate miR-223-3p, to precisely predict the progression and risk, even comorbidities or complications of the disease is of great value in the treatment of heart failure.
Whereas, in muscular dystrophy patients combined with advanced heart failure and a hypertension-induced congestive heart failure rat model, plasma miR-223-3p levels were elevated and positively correlated with circulating level of heart failure marker BNP and cardiac MYH7 expression in the animal model, which were upregulated in heart failure (155–159). It is noteworthy that there exist differences in circulating miRNAs signature between rodent heart failure models and human. The observed alteration of circulating miR-223-3p levels in heart failure patients did not occur in multiple rodent models with well-established heart failure (160). MiR-223-3p was identified to have similar sequences between human and mice, but different in rats. The diversity of miRNAs signature of different species may also due to the limitation of experimental animal models that could usually only mimic the heart failure symptoms caused by one stimulus but not accurately and roundly replicate the diverse pathogenesis of clinical human heart failure, and heart failure animal models are more likely to approximate the state of chronic heart failure in human. Furthermore, etiological factors in heart failure, such as hypertension, ischemia, and myocardial dystrophy, should also be considered when investigating the role of biomarkers related to heart failure.
Taken together, circulating levels of miR-223-3p are associated with the severity, current biomarkers for worse clinical outcomes, and the mortality of heart failure, as well as the risk of rehospitalization and concomitant diseases. Thus, circulating miR-223-3p level might not only evaluate the progression of heart failure but also act as a prognostic indicator or a predictor for comorbidities and complications of heart failure. Also, based on the regulatory networks of miR-223-3p in processes involved in heart failure, it is more likely to be a potential therapeutic target and serve as a biomarker to evaluate the treatment effects of heart failure.
MiR-223-3p in Other CVDs
MiR-223-3p in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is a serious and progressive disease commonly characterized by pulmonary arterial obstruction and elevated pulmonary arterial pressure (161). These conditions are commonly caused by excessive pulmonary vasoconstriction, inflammation, and pulmonary vascular remodeling, and are usually accompanied by hypoxic condition and dysfunction of pulmonary vasculature, leading to right ventricular failure or even death (161–163). As one of the most significant mechanisms involved in vascular remodeling of PAH, aberrant proliferation, migration, and apoptosis of pulmonary arterial endothelial cells and pulmonary arterial smooth muscle cells (PASMCs) affect the progression of PAH (164–166). Recent studies have verified the regulatory effects of miR-223-3p on PAH and PAH-related dysfunction of PASMCs.
MiR-223-3p was downregulated in lung, pulmonary arteries and PASMCs of both PAH patients and PAH models (167–169). In serum of female PAH patients associated with congenital heart disease, miR-223-3p levels were reduced compared with healthy females while there was no difference in males, suggesting the potential of miR-223-3p as a biomarker for PAH associated with congenital heart disease in females (168). Researchers have explored the specific mechanisms underlying the regulatory effects of miR-223-3p on PAH. HIF-1α, which is usually upregulated under hypoxia, was activated in PAH and led to the inhibition of miR-223-3p in PASMCs of PAH patients, resulting in upregulation of multiple miR-223-3p targets and the development of PAH (167–169). MiR-223-3p directly targeted integrin β 3 (ITGB3), IGF1R, poly (ADP-ribose) polymerase 1 (PARP1), ras homolog family member B (RHOB), and myosin light chain 2 (MYL2) in PASMCs to repress the proliferation and migration, and to promote the differentiation and DNA damage-induced apoptosis (167–172). Besides, the downregulation of miR-223-3p and upregulation of ITGB3 both increased the expression of IGF1R and PARP1, indicating that miR-223-3p could suppress IGF1R and PARP1 through direct regulation or by targeting ITGB3 (169). Therefore, both overexpression of miR-223-3p or suppression of ITGB3 regulated PASMCs activities to alleviate the pathological features of PAH animals including pulmonary vascular remodeling, pulmonary or myocardial hemorrhage, fibrosis of lung or myocardium, and right ventricular hypertrophy. The reverse of PAH phenotypes reduced the pulmonary resistance, improved the cardiac function, and finally prolonged the survival time of animals (167–169). Taken together, miR-223-3p inhibits PAH through directly targeting multiple genes and signaling pathways involved in abnormal activities of PASMCs and pulmonary vascular remodeling, so it might be a promising therapeutic target for PAH.
MiR-223-3p in Inflammation-Related Myocardial Disease
MiR-223-3p is considered to play a key role in inflammatory or immune responses during varieties of diseases through targeting different genes involved in monocytes differentiation, macrophages activation, and polarization, as well as regulation of eosinophil cells, resulting in modulation of both pro-inflammatory and anti-inflammatory signaling pathways (25, 30, 173). Myocarditis is a kind of inflammatory heart disease usually caused by infectious factors including virus and bacteria while non-infectious factors may also trigger the immune response in myocardium, such as autoimmune myocarditis (174, 175). Myocarditis has become one of the most common reasons for sudden death in children and young people (174, 176). It was reported that miR-223-3p displayed a protective function on both coxsackievirus B3 (CVB3)-induced viral myocarditis and autoimmune myocarditis, as well as on inflammation-related myocardial depression in polymicrobial sepsis (27, 177, 178).
In heart tissues and macrophages that infiltrated in hearts of CVB3-infected mice, the expression of miR-223-3p was downregulated, accompanied by elevation of PBX/knotted 1 homeobox 1 (PKNOX1). Upregulation of miR-223-3p altered the polarization phenotypes of macrophages from classical pro-inflammatory M1 type to alternative anti-inflammatory M2 type, partly depending on directly targeting PKNOX1 (177). This transition manifested as the inhibition of M1 markers such as nitric oxide synthase 2 and TNF-α, as well as the increase of M2 markers such as arginase-1 and fizz-1 (177, 179). These effects of miR-223-3p on macrophage activation and polarization made contributions to alleviating CVB3-induced inflammation and myocarditis with reducing pro-inflammatory and myocardial injury markers including interferon-γ, interleukin 6 (IL-6), creatine kinase MB, lactate dehydrogenase, and aspartate transaminase, as well as increasing the anti-inflammatory factor interleukin 10. As a result, miR-223-3p improved the indexes of cardiac function, body weights, and survival of CVB3-infected animals, indicating the alleviation of CVB3-induced myocarditis (177, 180, 181).
The protective role of miR-223-3p in autoimmune myocarditis lies in the regulation of another kind of immune cells, dendritic cells (DCs) which have been recognized as essential regulators to balance immunity and tolerance depending on their activation status (178, 182, 183). The tolerogenic DCs (tDCs) can be induced by immunosuppressive factors including interleukin 10 and TGF-β, leading to the unresponsiveness of T cells and tolerance of inflammatory stimulation, which is helpful in autoimmune diseases (184, 185). MiR-223-3p levels were reduced in serum and DCs of experimental autoimmune myocarditis mice while upregulating miR-223-3p in DCs prompted their transition to tDCs with reduced cellular surface markers of mature DCs and increased anti-inflammatory cytokines. MiR-223-3p also alleviated autoimmune myocarditis in vivo through reducing pericardial inflammation, increasing immunosuppressive response, and improving cardiac function. MiR-223-3p induced the transition of DCs to tDCs through directly targeting NLRP3, an important regulator to maintain immune homeostasis and tolerance, resulting in reduced production of NLRP3 inflammasome and its downstream signaling molecules such as caspase-1 and IL-1β (178).
In addition to myocarditis, miR-223-3p could also alleviate the myocardial depression in polymicrobial sepsis cooperated with miR-223-5p (27). Myocardial depression induced by sepsis is a major cause of cardiac dysfunction and septic cardiomyopathy, as well as increases the mortality in sepsis (186, 187). Both miR-223-3p and miR-223-5p were found downregulated in the polymicrobial sepsis model, and deficiency of miR-223(-3p/5p) weakened cardiac systolic function and reduced survival rate of animals in sepsis model. MiR-223(-3p/5p) deficiency also aggravated the inflammation induced by severe sepsis in myocardium, peritoneal fluid, and blood, with elevation of pro-inflammatory factors including TNF-α, IL-6, and IL-1β, increased bacterial load in body fluids, and neutrophil infiltration in hearts (27). The sepsis-induced myocardial depression can be inhibited via different pathways by miR-223-3p and miR-223-5p. MiR-223-3p targeted both signal transducer and activator of transcription 3 (STAT3) and IL-6 to inhibit the pro-inflammatory signaling pathway while miR-223-5p targeted semaphorin 3A to improve the autonomic control of cardiac function (27, 188). These effects of miR-223(-3p/5p) reduced the inflammation of heart and alleviated cardiac dysfunction, resulting in amelioration of myocardial depression and reduction of sudden death in severe sepsis (27, 189–191).
MiR-223-3p in Hypertension
Hypertension is one of the most common diseases and has become a major risk factor for many other diseases, such as myocardial infarction, stroke, and chronic renal failure (192–195). To overcome the clinical challenges of adverse effects of drugs and failure to achieve the optimum blood pressure control in hypertension, it requires earlier detection and accurate therapy to manage blood pressure and reduce its complications (196, 197). MiRNAs have been considered as useful biomarkers or indicators in many diseases depending on their properties such as high stability, easy detection, and low cost, to predict and evaluate the progression or risk of diseases as above-mentioned. Studies have illuminated the role of miRNAs in diagnosis and treatment of hypertension (198–200). A few researches have indicated that miR-223-3p might also be a promising biomarker for the diagnosis of hypertension and prediction of CVDs risk in hypertensive patients (201, 202).
Circulating miR-223-3p levels were downregulated in hypertensive patients, and the reduced serum miR-223-3p along with miR-199a-3p, miR-208a-3p, and miR-122-5p exhibited better diagnostic effects on hypertension than other miRNAs, with the highest sensitivity (202). Another research attempt to uncover the role of platelet miR-223-3p in hypertension and its related risk of CVDs. Platelets, which are abundant with miRNAs, are involved in the progression of hypertension-related pro-thrombotic status and blood pressure elevation during thrombogenesis (201, 203, 204). To explore the miRNAs in platelets could be helpful to screen biomarkers for hypertension. Platelet miR-223-3p levels decreased in hypertensive patients and the levels were negatively correlated with the systolic blood pressure of patients. Besides, the platelet levels of miR-223-3p in hypertensive patients were lower in patients with other CVDs, so platelet miR-223-3p could be a prognostic biomarker for hypertension (201). Therefore, both the circulating and platelet miR-223-3p might be developed into biomarkers for diagnosis and prognosis estimation of hypertension.
MiR-223-3p in Arrhythmia
Arrhythmia is an important category of CVDs and may occur alone or with other diseases. Severe or frequent arrhythmia attack could lead to hemodynamic disorder, heart failure, and sudden death. MiR-223-3p expression was increased in atrial tissues of atrial fibrillation (AF) patients with rheumatic heart disease, as well as in animal models of AF, suggesting the possible role of miR-223-3p involved in pathogenesis of AF (205). As we mentioned in previous parts, miR-223-3p induced arrhythmia following myocardial infarction through decreasing KCND2 and Ito, indicating the potential of miR-223-3p to regulate electrophysiological functions of myocardium (94). More effects of miR-223-3p in arrhythmia are worth investigating.
Conclusion
CVDs remain a major public health problem and result in heavy burden for human society. We have summarized the role of miR-223-3p in CVDs and recent developments in its potential as biomarker and therapeutic target for CVDs. MiR-223-3p is widely expressed in varieties of cell types that link to CVDs including monocytes, macrophages, platelets, hepatocytes, endothelial cells (resting state), cardiomyocytes, and cardiac fibroblasts to influence their cellular activities. These regulatory effects primarily depend on suppressing the mRNAs of target genes involved in lipid metabolism, inflammation, cell proliferation or apoptosis, electrophysiology, cell hypertrophy, and cell polarization (Table 1). Besides, MiR-223-3p participates in regulatory networks of multiple signaling pathways such as NFκB, MAPK, PI3K/AKT, RPS6KB1/HIF-1α, and NLRP3 inflammasome pathways to play diverse roles in CVDs (Table 2). Nevertheless, there still exist controversies about the effects of miR-223-3p in some CVDs. Studies to determine the specific role of circulating miR-223-3p for diagnosis and prediction of various CVDs are further needed. Future works to modulate the local level of miR-223-3p may lead to more effective treatment of CVDs.
Table 1. Verified target genes of miR-223-3p in CVDs.
Table 2. Signaling pathways regulated by miR-223-3p in CVDs.
Author Contributions
M-WZ: conceptualization and writing—original draft. Y-JS: literature collection. JS: visualization. J-GY: conceptualization and writing—review and editing. All authors contributed to the article and approved the submitted version.
Funding
This work was supported by grants from the Nurture projects for basic research of Shanghai Chest Hospital (2020YNJCM08 and 2020YNJCQ01).
Conflict of Interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1. World Health Statistics 2020: Monitoring Health for the SDGs Sustainable Development Goals. Geneva: World Health Organization (2020).
2. Thomas H, Diamond J, Vieco A, Chaudhuri S, Shinnar E, Cromer S, et al. Global atlas of cardiovascular disease 2000-2016: the path to prevention and control. Glob Heart. (2018) 13:143–63. doi: 10.1016/j.gheart.2018.09.511
3. Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. (2017) 70:1–25. doi: 10.1016/j.jacc.2017.04.052
4. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. (2012) 380:2095–128. doi: 10.1016/S0140-6736(12)61728-0
5. Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, et al. Demographic and epidemiologic drivers of global cardiovascular mortality. N Engl J Med. (2015) 372:1333–41. doi: 10.1056/NEJMoa1406656
6. Clark H. NCDs: a challenge to sustainable human development. Lancet. (2013) 381:510–1. doi: 10.1016/S0140-6736(13)60058-6
7. Mirzadeh Azad F, Arabian M, Maleki M, Malakootian M. Small molecules with big impacts on cardiovascular diseases. Biochem Genet. (2020) 58:359–83. doi: 10.1007/s10528-020-09948-z
8. Solly EL, Dimasi CG, Bursill CA, Psaltis PJ, Tan JTM. MicroRNAs as therapeutic targets and clinical biomarkers in atherosclerosis. J Clin Med. (2019) 8:2199. doi: 10.3390/jcm8122199
9. Barraclough JY, Joan M, Joglekar MV, Hardikar AA, Patel S. MicroRNAs as prognostic markers in acute coronary syndrome patients-a systematic review. Cells. (2019) 8.:1572. doi: 10.3390/cells8121572
10. Barwari T, Joshi A, Mayr M. MicroRNAs in cardiovascular disease. J Am Coll Cardiol. (2016) 68:2577–84. doi: 10.1016/j.jacc.2016.09.945
11. Mellis D, Caporali A. MicroRNA-based therapeutics in cardiovascular disease: screening and delivery to the target. Biochem Soc Trans. (2018) 46:11–21. doi: 10.1042/BST20170037
12. Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. (2004) 23:4051–60. doi: 10.1038/sj.emboj.7600385
13. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature. (2003) 425:415–9. doi: 10.1038/nature01957
14. Gregory RI, Yan KP, Amuthan G, Chendrimada T, Doratotaj B, Cooch N, et al. The Microprocessor complex mediates the genesis of microRNAs. Nature. (2004) 432:235–40. doi: 10.1038/nature03120
15. Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J. (2002) 21:4663–70. doi: 10.1093/emboj/cdf476
16. Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev. (2003) 17:3011–6. doi: 10.1101/gad.1158803
17. Noland CL, Doudna JA. Multiple sensors ensure guide strand selection in human RNAi pathways. RNA. (2013) 19:639–48. doi: 10.1261/rna.037424.112
18. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell. (2003) 115:209–16. doi: 10.1016/S0092-8674(03)00801-8
19. Meijer HA, Smith EM, Bushell M. Regulation of miRNA strand selection: follow the leader? Biochem Soc Trans. (2014) 42:1135–40. doi: 10.1042/BST20140142
20. Condrat CE, Thompson DC, Barbu MG, Bugnar OL, Boboc A, Cretoiu D, et al. miRNAs as biomarkers in disease: latest findings regarding their role in diagnosis and prognosis. Cells. (2020) 9:276. doi: 10.3390/cells9020276
21. O'Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol. (2018) 9:402. doi: 10.3389/fendo.2018.00402
22. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, et al. The microRNA spectrum in 12 body fluids. Clin Chem. (2010) 56:1733–41. doi: 10.1373/clinchem.2010.147405
23. Raposo G, Stoorvogel W. Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol. (2013) 200:373–83. doi: 10.1083/jcb.201211138
24. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol. (2011) 13:423–33. doi: 10.1038/ncb2210
25. Essandoh K, Li Y, Huo J, Fan GC. MiRNA-mediated macrophage polarization and its potential role in the regulation of inflammatory response. Shock. (2016) 46:122–31. doi: 10.1097/SHK.0000000000000604
26. Qin D, Wang X, Li Y, Yang L, Wang R, Peng J, et al. MicroRNA-223-5p and−3p cooperatively suppress necroptosis in ischemic/reperfused hearts. J Biol Chem. (2016) 291:20247–59. doi: 10.1074/jbc.M116.732735
27. Wang X, Huang W, Yang Y, Wang Y, Peng T, Chang J, et al. Loss of duplexmiR-223 (5p and 3p) aggravates myocardial depression and mortality in polymicrobial sepsis. Biochim Biophys Acta. (2014) 1842:701–11. doi: 10.1016/j.bbadis.2014.01.012
28. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science. (2004) 303:83–6. doi: 10.1126/science.1091903
29. Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, Kirak O, et al. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature. (2008) 451:1125–9. doi: 10.1038/nature06607
30. Aziz F. The emerging role of miR-223 as novel potential diagnostic and therapeutic target for inflammatory disorders. Cell Immunol. (2016) 303:1–6. doi: 10.1016/j.cellimm.2016.04.003
31. Haneklaus M, Gerlic M, O'Neill LA, Masters SL. miR-223: infection, inflammation and cancer. J Intern Med. (2013) 274:215–26. doi: 10.1111/joim.12099
32. Vickers KC, Landstreet SR, Levin MG, Shoucri BM, Toth CL, Taylor RC, et al. MicroRNA-223 coordinates cholesterol homeostasis. Proc Natl Acad Sci USA. (2014) 111:14518–23. doi: 10.1073/pnas.1215767111
33. Wang K, Long B, Liu F, Wang JX, Liu CY, Zhao B, et al. A circular RNA protects the heart from pathological hypertrophy and heart failure by targeting miR-223. Eur Heart J. (2016) 37:2602–11. doi: 10.1093/eurheartj/ehv713
34. Taibi F, Metzinger-Le Meuth V, Massy ZA, Metzinger L. miR-223: an inflammatory oncomiR enters the cardiovascular field. Biochim Biophys Acta. (2014) 1842:1001–9. doi: 10.1016/j.bbadis.2014.03.005
35. Shan Z, Qin S, Li W, Wu W, Yang J, Chu M, et al. An Endocrine genetic signal between blood cells and vascular smooth muscle cells: role of MicroRNA-223 in smooth muscle function and atherogenesis. J Am Coll Cardiol. (2015) 65:2526–37. doi: 10.1016/j.jacc.2015.03.570
36. Shi R, Zhou X, Ji WJ, Zhang YY, Ma YQ, Zhang JQ, et al. The emerging role of miR-223 in platelet reactivity: implications in antiplatelet therapy. Biomed Res Int. (2015) 2015:981841. doi: 10.1155/2015/981841
37. Dai GH, Ma PZ, Song XB, Liu N, Zhang T, Wu B. MicroRNA-223-3p inhibits the angiogenesis of ischemic cardiac microvascular endothelial cells via affecting RPS6KB1/hif-1a signal pathway. PLoS ONE. (2014) 9:e108468. doi: 10.1371/journal.pone.0108468
38. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell. (2001) 104:503–16. doi: 10.1016/S0092-8674(01)00238-0
39. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, et al. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Circulation. (2012) 125:1905–19. doi: 10.1161/CIRCULATIONAHA.111.066589
40. Pentikainen MO, Oorni K, Ala-Korpela M, Kovanen PT. Modified LDL - trigger of atherosclerosis and inflammation in the arterial intima. J Intern Med. (2000) 247:359–70. doi: 10.1046/j.1365-2796.2000.00655.x
41. Janas T, Janas T, Yarus M. Specific RNA binding to ordered phospholipid bilayers. Nucleic Acids Res. (2006) 34:2128–36. doi: 10.1093/nar/gkl220
42. Manavbasi Y, Suleymanoglu E. Nucleic acid-phospholipid recognition: fourier transform infrared spectrometric characterization of ternary phospholipid-inorganic cation-DNA complex and its relevance to chemicopharmaceutical design of nanometric liposome based gene delivery formulations. Arch Pharm Res. (2007) 30:1027–40. doi: 10.1007/BF02993973
43. Kim SI, Shin D, Choi TH, Lee JC, Cheon GJ, Kim KY, et al. Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I. Mol Ther. (2007) 15:1145–52. doi: 10.1038/sj.mt.6300168
44. Desgagne V, Guay SP, Guerin R, Corbin F, Couture P, Lamarche B, et al. Variations in HDL-carried miR-223 and miR-135a concentrations after consumption of dietary trans fat are associated with changes in blood lipid and inflammatory markers in healthy men - an exploratory study. Epigenetics. (2016) 11:438–48. doi: 10.1080/15592294.2016.1176816
45. Cuesta Torres LF, Zhu W, Ohrling G, Larsson R, Patel M, Wiese CB, et al. High-density lipoproteins induce miR-223-3p biogenesis and export from myeloid cells: role of scavenger receptor BI-mediated lipid transfer. Atherosclerosis. (2019) 286:20–9. doi: 10.1016/j.atherosclerosis.2019.04.227
46. Tabet F, Vickers KC, Cuesta Torres LF, Wiese CB, Shoucri BM, Lambert G, et al. HDL-transferred microRNA-223 regulates ICAM-1 expression in endothelial cells. Nat Commun. (2014) 5:3292. doi: 10.1038/ncomms4292
47. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high density lipoprotein receptor. Science. (1996) 271:518–20. doi: 10.1126/science.271.5248.518
48. Krieger M. Charting the fate of the “good cholesterol”: identification and characterization of the high-density lipoprotein receptor SR-BI. Annu Rev Biochem. (1999) 68:523–58. doi: 10.1146/annurev.biochem.68.1.523
49. Wang L, Jia XJ, Jiang HJ, Du Y, Yang F, Si SY, et al. MicroRNAs 185, 96, and 223 repress selective high-density lipoprotein cholesterol uptake through posttranscriptional inhibition. Mol Cell Biol. (2013) 33:1956–64. doi: 10.1128/MCB.01580-12
50. Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, et al. Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell. (2011) 19:232–43. doi: 10.1016/j.ccr.2011.01.001
51. Sun X, Belkin N, Feinberg MW. Endothelial microRNAs and atherosclerosis. Curr Atheroscler Rep. (2013) 15:372. doi: 10.1007/s11883-013-0372-2
52. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. (2012) 32:2045–51. doi: 10.1161/ATVBAHA.108.179705
53. Schachter M. Vascular smooth muscle cell migration, atherosclerosis, and calcium channel blockers. Int J Cardiol. (1997) 62(Suppl. 2):S85–90. doi: 10.1016/S0167-5273(97)00245-3
54. Li J, Tan M, Xiang Q, Zhou Z, Yan H. Thrombin-activated platelet-derived exosomes regulate endothelial cell expression of ICAM-1 via microRNA-223 during the thrombosis-inflammation response. Thromb Res. (2017) 154:96–105. doi: 10.1016/j.thromres.2017.04.016
55. Leierseder S, Petzold T, Zhang L, Loyer X, Massberg S, Engelhardt S. MiR-223 is dispensable for platelet production and function in mice. Thromb Haemost. (2013) 110:1207–14. doi: 10.1160/TH13-07-0623
56. Ismail N, Wang Y, Dakhlallah D, Moldovan L, Agarwal K, Batte K, et al. Macrophage microvesicles induce macrophage differentiation and miR-223 transfer. Blood. (2013) 121:984–95. doi: 10.1182/blood-2011-08-374793
57. Wang J, Bai X, Song Q, Fan F, Hu Z, Cheng G, et al. miR-223 inhibits lipid deposition and inflammation by suppressing toll-like receptor 4 signaling in macrophages. Int J Mol Sci. (2015) 16:24965–82. doi: 10.3390/ijms161024965
58. Wolfs IM, Donners MM, de Winther MP. Differentiation factors and cytokines in the atherosclerotic plaque micro-environment as a trigger for macrophage polarisation. Thromb Haemost. (2011) 106:763–71. doi: 10.1160/TH11-05-0320
59. Rangrez AY, M'Baya-Moutoula E, Metzinger-Le Meuth V, Henaut L, Djelouat MS, Benchitrit J, et al. Inorganic phosphate accelerates the migration of vascular smooth muscle cells: evidence for the involvement of miR-223. PLoS ONE. (2012) 7:e47807. doi: 10.1371/journal.pone.0047807
60. M'Baya-Moutoula E, Marchand A, Six I, Bahrar N, Celic T, Mougenot N, et al. Inhibition of miR-223 expression using a sponge strategy decreases restenosis in rat injured carotids. Curr Vasc Pharmacol. (2019) 18:507–16. doi: 10.2174/1570161117666190705141152
61. Nagalla S, Shaw C, Kong X, Kondkar AA, Edelstein LC, Ma L, et al. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood. (2011) 117:5189–97. doi: 10.1182/blood-2010-09-299719
62. Willeit P, Zampetaki A, Dudek K, Kaudewitz D, King A, Kirkby NS, et al. Circulating microRNAs as novel biomarkers for platelet activation. Circ Res. (2013) 112:595–600. doi: 10.1161/CIRCRESAHA.111.300539
63. Osman A, Falker K. Characterization of human platelet microRNA by quantitative PCR coupled with an annotation network for predicted target genes. Platelets. (2011) 22:433–41. doi: 10.3109/09537104.2011.560305
64. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, et al. Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE. (2008) 3:e3694. doi: 10.1371/journal.pone.0003694
65. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. (2008) 18:997–1006. doi: 10.1038/cr.2008.282
66. Kin K, Miyagawa S, Fukushima S, Shirakawa Y, Torikai K, Shimamura K, et al. Tissue- and plasma-specific MicroRNA signatures for atherosclerotic abdominal aortic aneurysm. J Am Heart Assoc. (2012) 1:e000745. doi: 10.1161/JAHA.112.000745
67. Vegter EL, Ovchinnikova ES, van Veldhuisen DJ, Jaarsma T, Berezikov E, van der Meer P, et al. Low circulating microRNA levels in heart failure patients are associated with atherosclerotic disease and cardiovascular-related rehospitalizations. Clin Res Cardiol. (2017) 106:598–609. doi: 10.1007/s00392-017-1096-z
68. Alexandru N, Constantin A, Nemecz M, Comarita IK, Vilcu A, Procopciuc A, et al. Hypertension associated with hyperlipidemia induced different MicroRNA expression profiles in plasma, platelets, and platelet-derived microvesicles; effects of endothelial progenitor cell therapy. Front Med. (2019) 6:280. doi: 10.3389/fmed.2019.00280
69. Wu MY, Li CJ, Hou MF, Chu PY. New insights into the role of inflammation in the pathogenesis of atherosclerosis. Int J Mol Sci. (2017) 18:2034. doi: 10.3390/ijms18102034
70. Thomas MR, Lip GY. Novel risk markers and risk assessments for cardiovascular disease. Circ Res. (2017) 120:133–49. doi: 10.1161/CIRCRESAHA.116.309955
71. Teringova E, Tousek P. Apoptosis in ischemic heart disease. J Transl Med. (2017) 15:87. doi: 10.1186/s12967-017-1191-y
72. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev. (1999) 79:215–62. doi: 10.1152/physrev.1999.79.1.215
73. Bouzeghrane F, Reinhardt DP, Reudelhuber TL, Thibault G. Enhanced expression of fibrillin-1, a constituent of the myocardial extracellular matrix in fibrosis. Am J Physiol Heart Circ Physiol. (2005) 289:H982–91. doi: 10.1152/ajpheart.00151.2005
74. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, West AB. Myofibroblasts. I. Paracrine cells important in health and disease. Am J Physiol. (1999) 277:C1–9. doi: 10.1152/ajpcell.1999.277.1.C1
75. Gershlick AH, Banning AP, Myat A, Verheugt FW, Gersh BJ. Reperfusion therapy for STEMI: is there still a role for thrombolysis in the era of primary percutaneous coronary intervention? Lancet. (2013) 382:624–32. doi: 10.1016/S0140-6736(13)61454-3
76. Frohlich GM, Meier P, White SK, Yellon DM, Hausenloy DJ. Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J. (2013) 34:1714–22. doi: 10.1093/eurheartj/eht090
77. Zhu H, Fan GC. Role of microRNAs in the reperfused myocardium towards post-infarct remodelling. Cardiovasc Res. (2012) 94:284–92. doi: 10.1093/cvr/cvr291
78. Kang TB, Yang SH, Toth B, Kovalenko A, Wallach D. Activation of the NLRP3 inflammasome by proteins that signal for necroptosis. Methods Enzymol. (2014) 545:67–81. doi: 10.1016/B978-0-12-801430-1.00003-2
79. Cullen SP, Kearney CJ, Clancy DM, Martin SJ. Diverse activators of the NLRP3 inflammasome promote IL-1beta secretion by triggering necrosis. Cell Rep. (2015) 11:1535–48. doi: 10.1016/j.celrep.2015.05.003
80. Silke J, Rickard JA, Gerlic M. The diverse role of RIP kinases in necroptosis and inflammation. Nat Immunol. (2015) 16:689–97. doi: 10.1038/ni.3206
81. Shi L, Fisslthaler B, Zippel N, Fromel T, Hu J, Elgheznawy A, et al. MicroRNA-223 antagonizes angiogenesis by targeting beta1 integrin and preventing growth factor signaling in endothelial cells. Circ Res. (2013) 113:1320–30. doi: 10.1161/CIRCRESAHA.113.301824
82. Tang Q, Li MY, Su YF, Fu J, Zou ZY, Wang Y, et al. Absence of miR-223-3p ameliorates hypoxia-induced injury through repressing cardiomyocyte apoptosis and oxidative stress by targeting KLF15. Eur J Pharmacol. (2018) 841:67–74. doi: 10.1016/j.ejphar.2018.10.014
83. Zhang J, He Z, Xiao W, Na Q, Wu T, Su K, et al. Overexpression of BAG3 attenuates hypoxia-induced cardiomyocyte apoptosis by inducing autophagy. Cell Physiol Biochem. (2016) 39:491–500. doi: 10.1159/000445641
84. Chouvarine P, Legchenko E, Geldner J, Riehle C, Hansmann G. Hypoxia drives cardiac miRNAs and inflammation in the right and left ventricle. J Mol Med. (2019) 97:1427–38. doi: 10.1007/s00109-019-01817-6
85. Liu X, Xu Y, Deng Y, Li H. MicroRNA-223 regulates cardiac fibrosis after myocardial infarction by targeting RASA1. Cell Physiol Biochem. (2018) 46:1439–54. doi: 10.1159/000489185
86. Zamilpa R, Lindsey ML. Extracellular matrix turnover and signaling during cardiac remodeling following MI: causes and consequences. J Mol Cell Cardiol. (2010) 48:558–63. doi: 10.1016/j.yjmcc.2009.06.012
87. Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. (2002) 3:349–63. doi: 10.1038/nrm809
88. van den Borne SW, Diez J, Blankesteijn WM, Verjans J, Hofstra L, Narula J. Myocardial remodeling after infarction: the role of myofibroblasts. Nat Rev Cardiol. (2010) 7:30–7. doi: 10.1038/nrcardio.2009.199
89. Morishita Y, Yoshizawa H, Watanabe M, Imai R, Imai T, Hirahara I, et al. MicroRNA expression profiling in peritoneal fibrosis. Transl Res. (2016) 169:47–66. doi: 10.1016/j.trsl.2015.10.009
90. Kaprielian R, Wickenden AD, Kassiri Z, Parker TG, Liu PP, Backx PH. Relationship between K+ channel down-regulation and [Ca2+]i in rat ventricular myocytes following myocardial infarction. J Physiol. (1999) 517 (Pt 1):229–45. doi: 10.1111/j.1469-7793.1999.0229z.x
91. Kaprielian R, Sah R, Nguyen T, Wickenden AD, Backx PH. Myocardial infarction in rat eliminates regional heterogeneity of AP profiles, I(to) K(+) currents, and [Ca(2+)](i) transients. Am J Physiol Heart Circ Physiol. (2002) 283:H1157–68. doi: 10.1152/ajpheart.00518.2001
92. Volk T, Nguyen TH, Schultz JH, Faulhaber J, Ehmke H. Regional alterations of repolarizing K+ currents among the left ventricular free wall of rats with ascending aortic stenosis. J Physiol. (2001) 530(Pt 3):443–55. doi: 10.1111/j.1469-7793.2001.0443k.x
93. Wang Z, Feng J, Shi H, Pond A, Nerbonne JM, Nattel S. Potential molecular basis of different physiological properties of the transient outward K+ current in rabbit and human atrial myocytes. Circ Res. (1999) 84:551–61. doi: 10.1161/01.RES.84.5.551
94. Liu X, Zhang Y, Du W, Liang H, He H, Zhang L, et al. MiR-223-3p as a novel MicroRNA regulator of expression of voltage-gated K+ channel Kv4.2 in acute myocardial infarction. Cell Physiol Biochem. (2016) 39:102–14. doi: 10.1159/000445609
95. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA. (2008) 105:13027–32. doi: 10.1073/pnas.0805038105
96. Carino A, De Rosa S, Sorrentino S, Polimeni A, Sabatino J, Caiazzo G, et al. Modulation of circulating MicroRNAs levels during the switch from clopidogrel to ticagrelor. Biomed Res Int. (2016) 2016:3968206. doi: 10.1155/2016/3968206
97. Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey DE Jr, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. (2012) 60:645–81. doi: 10.1161/CIR.0b013e318256f1e0
98. Aradi D, Komocsi A, Vorobcsuk A, Rideg O, Tokes-Fuzesi M, Magyarlaki T, et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am Heart J. (2010) 160:543–51. doi: 10.1016/j.ahj.2010.06.004
99. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Harmsze AM, Hackeng CM, et al. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention. Heart. (2011) 97:983–90. doi: 10.1136/hrt.2010.220491
100. Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O'Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “boxed warning”: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents and the American Heart Association endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol. (2010) 56:321–41. doi: 10.1016/j.jacc.2010.05.013
101. Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation. (2004) 109:3171–5. doi: 10.1161/01.CIR.0000130846.46168.03
102. Zampetaki A, Willeit P, Tilling L, Drozdov I, Prokopi M, Renard JM, et al. Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol. (2012) 60:290–9. doi: 10.1016/j.jacc.2012.03.056
103. Landry P, Plante I, Ouellet DL, Perron MP, Rousseau G, Provost P. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol. (2009) 16:961–6. doi: 10.1038/nsmb.1651
104. Zhang YY, Zhou X, Ji WJ, Shi R, Lu RY, Li JL, et al. Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome. J Thromb Thrombolysis. (2014) 38:65–72. doi: 10.1007/s11239-013-1022-9
105. Shi R, Ge L, Zhou X, Ji WJ, Lu RY, Zhang YY, et al. Decreased platelet miR-223 expression is associated with high on-clopidogrel platelet reactivity. Thromb Res. (2013) 131:508–13. doi: 10.1016/j.thromres.2013.02.015
106. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost. (2005) 3:85–92. doi: 10.1111/j.1538-7836.2004.01063.x
107. Cuisset T, Frere C, Quilici J, Barbou F, Morange PE, Hovasse T, et al. High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome. J Thromb Haemost. (2006) 4:542–9. doi: 10.1111/j.1538-7836.2005.01751.x
108. Cuisset T, Cayla G, Frere C, Quilici J, Poyet R, Gaborit B, et al. Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment? EuroIntervention. (2009) 5:325–9. doi: 10.4244/51
109. Chyrchel B, Toton-Zuranska J, Kruszelnicka O, Chyrchel M, Mielecki W, Kolton-Wroz M, et al. Association of plasma miR-223 and platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy: a preliminary report. Platelets. (2015) 26:593–7. doi: 10.3109/09537104.2014.974527
110. Chen YC, Lin FY, Lin YW, Cheng SM, Chang CC, Lin RH, et al. Platelet MicroRNA 365-3p expression correlates with high on-treatment platelet reactivity in coronary artery disease patients. Cardiovasc Drugs Ther. (2019) 33:129–37. doi: 10.1007/s10557-019-06855-3
111. Guo JF, Zhang Y, Zheng QX, Zhang Y, Zhou HH, Cui LM. Association between elevated plasma microRNA-223 content and severity of coronary heart disease. Scand J Clin Lab Invest. (2018) 78:373–8. doi: 10.1080/00365513.2018.1480059
112. Schulte C, Molz S, Appelbaum S, Karakas M, Ojeda F, Lau DM, et al. miRNA-197 and miRNA-223 predict cardiovascular death in a cohort of patients with symptomatic coronary artery disease. PLoS ONE. (2015) 10:e0145930. doi: 10.1371/journal.pone.0145930
113. Choteau SA, Cuesta Torres LF, Barraclough JY, Elder AMM, Martinez GJ, Chen Fan WY, et al. Transcoronary gradients of HDL-associated MicroRNAs in unstable coronary artery disease. Int J Cardiol. (2018) 253:138–44. doi: 10.1016/j.ijcard.2017.09.190
114. Li C, Fang Z, Jiang T, Zhang Q, Liu C, Zhang C, et al. Serum microRNAs profile from genome-wide serves as a fingerprint for diagnosis of acute myocardial infarction and angina pectoris. BMC Med Genomics. (2013) 6:16. doi: 10.1186/1755-8794-6-16
115. Saadatian Z, Nariman-Saleh-Fam Z, Bastami M, Mansoori Y, Khaheshi I, Parsa SA, et al. Dysregulated expression of STAT1, miR-150, and miR-223 in peripheral blood mononuclear cells of coronary artery disease patients with significant or insignificant stenosis. J Cell Biochem. (2019) 120:19810–24. doi: 10.1002/jcb.29286
116. Burchfield JS, Xie M, Hill JA. Pathological ventricular remodeling: mechanisms: part 1 of 2. Circulation. (2013) 128:388–400. doi: 10.1161/CIRCULATIONAHA.113.001878
117. Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Executive summary: heart disease and stroke statistics−2010 update: a report from the American Heart Association. Circulation. (2010) 121:948–54. doi: 10.1161/CIRCULATIONAHA.109.192666
118. Samak M, Fatullayev J, Sabashnikov A, Zeriouh M, Schmack B, Farag M, et al. Cardiac hypertrophy: an introduction to molecular and cellular basis. Med Sci Monit Basic Res. (2016) 22:75–9. doi: 10.12659/MSMBR.900437
119. Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. (2006) 48:1977–85. doi: 10.1016/j.jacc.2006.07.049
120. Bisping E, Wakula P, Poteser M, Heinzel FR. Targeting cardiac hypertrophy: toward a causal heart failure therapy. J Cardiovasc Pharmacol. (2014) 64:293–305. doi: 10.1097/FJC.0000000000000126
121. Orenes-Pinero E, Montoro-Garcia S, Patel JV, Valdes M, Marin F, Lip GY. Role of microRNAs in cardiac remodelling: new insights and future perspectives. Int J Cardiol. (2013) 167:1651–9. doi: 10.1016/j.ijcard.2012.09.120
122. Frieler RA, Mortensen RM. Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation. (2015) 131:1019–30. doi: 10.1161/CIRCULATIONAHA.114.008788
123. Heymans S, Hirsch E, Anker SD, Aukrust P, Balligand JL, Cohen-Tervaert JW, et al. Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. (2009) 11:119–29. doi: 10.1093/eurjhf/hfn043
124. Wang YS, Zhou J, Hong K, Cheng XS, Li YG. MicroRNA-223 displays a protective role against cardiomyocyte hypertrophy by targeting cardiac troponin I-interacting kinase. Cell Physiol Biochem. (2015) 35:1546–56. doi: 10.1159/000373970
125. Zhao ZH, Luo J, Li HX, Wang SH, Li XM. SOX2-mediated inhibition of miR-223 contributes to STIM1 activation in phenylephrine-induced hypertrophic cardiomyocytes. Mol Cell Biochem. (2018) 443:47–56. doi: 10.1007/s11010-017-3209-4
126. Heallen T, Zhang M, Wang J, Bonilla-Claudio M, Klysik E, Johnson RL, et al. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science. (2011) 332:458–61. doi: 10.1126/science.1199010
127. Pan Z, Brotto M, Ma J. Store-operated Ca2+ entry in muscle physiology and diseases. BMB Rep. (2014) 47:69–79. doi: 10.5483/BMBRep.2014.47.2.015
128. Luo X, Hojayev B, Jiang N, Wang ZV, Tandan S, Rakalin A, et al. STIM1-dependent store-operated Ca(2)(+) entry is required for pathological cardiac hypertrophy. J Mol Cell Cardiol. (2012) 52:136–47. doi: 10.1016/j.yjmcc.2011.11.003
129. Ohba T, Watanabe H, Murakami M, Sato T, Ono K, Ito H. Essential role of STIM1 in the development of cardiomyocyte hypertrophy. Biochem Biophys Res Commun. (2009) 389:172–6. doi: 10.1016/j.bbrc.2009.08.117
130. Tang H, Xiao K, Mao L, Rockman HA, Marchuk DA. Overexpression of TNNI3K, a cardiac-specific MAPKKK, promotes cardiac dysfunction. J Mol Cell Cardiol. (2013) 54:101–11. doi: 10.1016/j.yjmcc.2012.10.004
131. Wang L, Wang H, Ye J, Xu RX, Song L, Shi N, et al. Adenovirus-mediated overexpression of cardiac troponin I-interacting kinase promotes cardiomyocyte hypertrophy. Clin Exp Pharmacol Physiol. (2011) 38:278–84. doi: 10.1111/j.1440-1681.2011.05499.x
132. Wang X, Wang J, Su M, Wang C, Chen J, Wang H, et al. TNNI3K, a cardiac-specific kinase, promotes physiological cardiac hypertrophy in transgenic mice. PLoS ONE. (2013) 8:e58570. doi: 10.1371/journal.pone.0058570
133. Greco S, Fasanaro P, Castelvecchio S, D'Alessandra Y, Arcelli D, Di Donato M, et al. MicroRNA dysregulation in diabetic ischemic heart failure patients. Diabetes. (2012) 61:1633–41. doi: 10.2337/db11-0952
134. Barsanti C, Trivella MG, D'Aurizio R, El Baroudi M, Baumgart M, Groth M, et al. Differential regulation of microRNAs in end-stage failing hearts is associated with left ventricular assist device unloading. Biomed Res Int. (2015) 2015:592512. doi: 10.1155/2015/592512
135. Verma SK, Krishnamurthy P, Barefield D, Singh N, Gupta R, Lambers E, et al. Interleukin-10 treatment attenuates pressure overload-induced hypertrophic remodeling and improves heart function via signal transducers and activators of transcription 3-dependent inhibition of nuclear factor-kappaB. Circulation. (2012) 126:418–29. doi: 10.1161/CIRCULATIONAHA.112.112185
136. Kashihara T, Nakada T, Shimojo H, Horiuchi-Hirose M, Gomi S, Shibazaki T, et al. Chronic receptor-mediated activation of Gi/o proteins alters basal t-tubular and sarcolemmal L-type Ca(2)(+) channel activity through phosphatases in heart failure. Am J Physiol Heart Circ Physiol. (2012) 302:H1645–54. doi: 10.1152/ajpheart.00589.2011
137. Yang L, Li Y, Wang X, Mu X, Qin D, Huang W, et al. Overexpression of miR-223 tips the balance of pro- and anti-hypertrophic signaling cascades toward physiologic cardiac hypertrophy. J Biol Chem. (2016) 291:15700–13. doi: 10.1074/jbc.M116.715805
138. Donath S, Li P, Willenbockel C, Al-Saadi N, Gross V, Willnow T, et al. Apoptosis repressor with caspase recruitment domain is required for cardioprotection in response to biomechanical and ischemic stress. Circulation. (2006) 113:1203–12. doi: 10.1161/CIRCULATIONAHA.105.576785
139. Murtaza I, Wang HX, Feng X, Alenina N, Bader M, Prabhakar BS, et al. Down-regulation of catalase and oxidative modification of protein kinase CK2 lead to the failure of apoptosis repressor with caspase recruitment domain to inhibit cardiomyocyte hypertrophy. J Biol Chem. (2008) 283:5996–6004. doi: 10.1074/jbc.M706466200
140. Maillet M, van Berlo JH, Molkentin JD. Molecular basis of physiological heart growth: fundamental concepts and new players. Nat Rev Mol Cell Biol. (2013) 14:38–48. doi: 10.1038/nrm3495
141. Bernardo BC, Weeks KL, Pretorius L, McMullen JR. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol Ther. (2010) 128:191–227. doi: 10.1016/j.pharmthera.2010.04.005
142. Yeves AM, Villa-Abrille MC, Perez NG, Medina AJ, Escudero EM, Ennis IL. Physiological cardiac hypertrophy: critical role of AKT in the prevention of NHE-1 hyperactivity. J Mol Cell Cardiol. (2014) 76:186–95. doi: 10.1016/j.yjmcc.2014.09.004
143. Moc C, Taylor AE, Chesini GP, Zambrano CM, Barlow MS, Zhang X, et al. Physiological activation of Akt by PHLPP1 deletion protects against pathological hypertrophy. Cardiovasc Res. (2015) 105:160–70. doi: 10.1093/cvr/cvu243
144. Verjans R, Derks WJA, Korn K, Sonnichsen B, van Leeuwen REW, Schroen B, et al. Functional screening identifies MicroRNAs as multi-cellular regulators of heart failure. Sci Rep. (2019) 9:6055. doi: 10.1038/s41598-019-41491-9
145. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. (2012) 14:803–69. doi: 10.1093/eurheartj/ehs104
146. Derda AA, Thum S, Lorenzen JM, Bavendiek U, Heineke J, Keyser B, et al. Blood-based microRNA signatures differentiate various forms of cardiac hypertrophy. Int J Cardiol. (2015) 196:115–22. doi: 10.1016/j.ijcard.2015.05.185
147. Vegter EL, van der Meer P, de Windt LJ, Pinto YM, Voors AA. MicroRNAs in heart failure: from biomarker to target for therapy. Eur J Heart Fail. (2016) 18:457–68. doi: 10.1002/ejhf.495
148. Marfella R, Di Filippo C, Potenza N, Sardu C, Rizzo MR, Siniscalchi M, et al. Circulating microRNA changes in heart failure patients treated with cardiac resynchronization therapy: responders vs. non-responders. Eur J Heart Fail. (2013) 15:1277–88. doi: 10.1093/eurjhf/hft088
149. Ovchinnikova ES, Schmitter D, Vegter EL, Ter Maaten JM, Valente MA, Liu LC, et al. Signature of circulating microRNAs in patients with acute heart failure. Eur J Heart Fail. (2016) 18:414–23. doi: 10.1002/ejhf.332
150. Vegter EL, Schmitter D, Hagemeijer Y, Ovchinnikova ES, van der Harst P, Teerlink JR, et al. Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. Int J Cardiol. (2016) 224:231–9. doi: 10.1016/j.ijcard.2016.09.010
151. Damman K, Valente MA, Voors AA, O'Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. (2014) 35:455–69. doi: 10.1093/eurheartj/eht386
152. Bruno N, ter Maaten JM, Ovchinnikova ES, Vegter EL, Valente MA, van der Meer P, et al. MicroRNAs relate to early worsening of renal function in patients with acute heart failure. Int J Cardiol. (2016) 203:564–69. doi: 10.1016/j.ijcard.2015.10.217
153. Saikumar J, Hoffmann D, Kim TM, Gonzalez VR, Zhang Q, Goering PL, et al. Expression, circulation, and excretion profile of microRNA-21,−155, and−18a following acute kidney injury. Toxicol Sci. (2012) 129:256–67. doi: 10.1093/toxsci/kfs210
154. Kaucsar T, Revesz C, Godo M, Krenacs T, Albert M, Szalay CI, et al. Activation of the miR-17 family and miR-21 during murine kidney ischemia-reperfusion injury. Nucleic Acid Ther. (2013) 23:344–54. doi: 10.1089/nat.2013.0438
155. Matsumura T, Matsui M, Iwata Y, Asakura M, Saito T, Fujimura H, et al. A pilot study of tranilast for cardiomyopathy of muscular dystrophy. Intern Med. (2018) 57:311–8. doi: 10.2169/internalmedicine.8651-16
156. Dickinson BA, Semus HM, Montgomery RL, Stack C, Latimer PA, Lewton SM, et al. Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure. Eur J Heart Fail. (2013) 15:650–9. doi: 10.1093/eurjhf/hft018
157. Dahl LK, Knudsen KD, Heine MA, Leitl GJ. Effects of chronic excess salt ingestion. Modification of experimental hypertension in the rat by variations in the diet. Circ Res. (1968) 22:11–8. doi: 10.1161/01.RES.22.1.11
158. Pfeffer MA, Pfeffer J, Mirsky I, Iwai J. Cardiac hypertrophy and performance of Dahl hypertensive rats on graded salt diets. Hypertension. (1984) 6:475–81. doi: 10.1161/01.HYP.6.4.475
159. Gupta MP. Factors controlling cardiac myosin-isoform shift during hypertrophy and heart failure. J Mol Cell Cardiol. (2007) 43:388–403. doi: 10.1016/j.yjmcc.2007.07.045
160. Vegter EL, Ovchinnikova ES, Sillje HHW, Meems LMG, van der Pol A, van der Velde AR, et al. Rodent heart failure models do not reflect the human circulating microRNA signature in heart failure. PLoS ONE. (2017) 12:e0177242. doi: 10.1371/journal.pone.0177242
161. Humbert M, Sitbon O, Yaici A, Montani D, O'Callaghan DS, Jais X, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. (2010) 36:549–55. doi: 10.1183/09031936.00057010
162. Archer SL, Weir EK, Wilkins MR. Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation. (2010) 121:2045–66. doi: 10.1161/CIRCULATIONAHA.108.847707
163. Negi V, Chan SY. Discerning functional hierarchies of microRNAs in pulmonary hypertension. JCI Insight. (2017) 2:e91327. doi: 10.1172/jci.insight.91327
164. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol. (2004) 43(12 Suppl S):13S−24S. doi: 10.1016/j.jacc.2004.02.029
165. Crosswhite P, Sun Z. Molecular mechanisms of pulmonary arterial remodeling. Mol Med. (2014) 20:191–201. doi: 10.2119/molmed.2013.00165
166. Li L, Kim IK, Chiasson V, Chatterjee P, Gupta S. NF-kappaB mediated miR-130a modulation in lung microvascular cell remodeling: Implication in pulmonary hypertension. Exp Cell Res. (2017) 359:235–42. doi: 10.1016/j.yexcr.2017.07.024
167. Meloche J, Le Guen M, Potus F, Vinck J, Ranchoux B, Johnson I, et al. miR-223 reverses experimental pulmonary arterial hypertension. Am J Physiol Cell Physiol. (2015) 309:C363–72. doi: 10.1152/ajpcell.00149.2015
168. Zeng Y, Zhang X, Kang K, Chen J, Wu Z, Huang J, et al. MicroRNA-223 attenuates hypoxia-induced vascular remodeling by targeting RhoB/MLC2 in pulmonary arterial smooth muscle cells. Sci Rep. (2016) 6:24900. doi: 10.1038/srep24900
169. Liu A, Liu Y, Li B, Yang M, Liu Y, Su J. Role of miR-223-3p in pulmonary arterial hypertension via targeting ITGB3 in the ECM pathway. Cell Prolif . (2019) 52:e12550. doi: 10.1111/cpr.12550
170. Shi L, Kojonazarov B, Elgheznawy A, Popp R, Dahal BK, Bohm M, et al. miR-223-IGF-IR signalling in hypoxia- and load-induced right-ventricular failure: a novel therapeutic approach. Cardiovasc Res. (2016) 111:184–93. doi: 10.1093/cvr/cvw065
171. Liu X, Deng Y, Xu Y, Jin W, Li H. MicroRNA-223 protects neonatal rat cardiomyocytes and H9c2 cells from hypoxia-induced apoptosis and excessive autophagy via the Akt/mTOR pathway by targeting PARP-1. J Mol Cell Cardiol. (2018) 118:133–46. doi: 10.1016/j.yjmcc.2018.03.018
172. Meloche J, Pflieger A, Vaillancourt M, Paulin R, Potus F, Zervopoulos S, et al. Role for DNA damage signaling in pulmonary arterial hypertension. Circulation. (2014) 129:786–97. doi: 10.1161/CIRCULATIONAHA.113.006167
173. Zhuang G, Meng C, Guo X, Cheruku PS, Shi L, Xu H, et al. A novel regulator of macrophage activation: miR-223 in obesity-associated adipose tissue inflammation. Circulation. (2012) 125:2892–903. doi: 10.1161/CIRCULATIONAHA.111.087817
174. Sagar S, Liu PP, Cooper LT Jr. Myocarditis. Lancet. (2012) 379:738–47. doi: 10.1016/S0140-6736(11)60648-X
175. Rose NR. Myocarditis: infection versus autoimmunity. J Clin Immunol. (2009) 29:730–7. doi: 10.1007/s10875-009-9339-z
176. Steinberger J, Lucas RV, Jr, Edwards JE, Titus JL. Causes of sudden unexpected cardiac death in the first two decades of life. Am J Cardiol. (1996) 77:992–5. doi: 10.1016/S0002-9149(96)00035-5
177. Gou W, Zhang Z, Yang C, Li Y. MiR-223/Pknox1 axis protects mice from CVB3-induced viral myocarditis by modulating macrophage polarization. Exp Cell Res. (2018) 366:41–8. doi: 10.1016/j.yexcr.2018.03.004
178. Chen L, Hou X, Zhang M, Zheng Y, Zheng X, Yang Q, et al. MicroRNA-223-3p modulates dendritic cell function and ameliorates experimental autoimmune myocarditis by targeting the NLRP3 inflammasome. Mol Immunol. (2020) 117:73–83. doi: 10.1016/j.molimm.2019.10.027
179. Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. (2012) 122:787–95. doi: 10.1172/JCI59643
180. Wang C, Dong C, Xiong S. IL-33 enhances macrophage M2 polarization and protects mice from CVB3-induced viral myocarditis. J Mol Cell Cardiol. (2017) 103:22–30. doi: 10.1016/j.yjmcc.2016.12.010
181. He J, Yue Y, Dong C, Xiong S. MiR-21 confers resistance against CVB3-induced myocarditis by inhibiting PDCD4-mediated apoptosis. Clin Invest Med. (2013) 36:E103–11. doi: 10.25011/cim.v36i2.19573
182. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med. (1973) 137:1142–62. doi: 10.1084/jem.137.5.1142
183. Svajger U, Rozman P. Induction of tolerogenic dendritic cells by endogenous biomolecules: an update. Front Immunol. (2018) 9:2482. doi: 10.3389/fimmu.2018.02482
184. Osorio F, Fuentes C, Lopez MN, Salazar-Onfray F, Gonzalez FE. Role of dendritic cells in the induction of lymphocyte tolerance. Front Immunol. (2015) 6:535. doi: 10.3389/fimmu.2015.00535
185. Hongo D, Tang X, Zhang X, Engleman EG, Strober S. Tolerogenic interactions between CD8(+) dendritic cells and NKT cells prevent rejection of bone marrow and organ grafts. Blood. (2017) 129:1718–28. doi: 10.1182/blood-2016-07-723015
186. Romero-Bermejo FJ, Ruiz-Bailen M, Gil-Cebrian J, Huertos-Ranchal MJ. Sepsis-induced cardiomyopathy. Curr Cardiol Rev. (2011) 7:163–83. doi: 10.2174/157340311798220494
187. Hochstadt A, Meroz Y, Landesberg G. Myocardial dysfunction in severe sepsis and septic shock: more questions than answers? J Cardiothorac Vasc Anesth. (2011) 25:526–35. doi: 10.1053/j.jvca.2010.11.026
188. Ieda M, Kanazawa H, Kimura K, Hattori F, Ieda Y, Taniguchi M, et al. Sema3a maintains normal heart rhythm through sympathetic innervation patterning. Nat Med. (2007) 13:604–12. doi: 10.1038/nm1570
189. Zhang H, Wang HY, Bassel-Duby R, Maass DL, Johnston WE, Horton JW, et al. Role of interleukin-6 in cardiac inflammation and dysfunction after burn complicated by sepsis. Am J Physiol Heart Circ Physiol. (2007) 292:H2408–16. doi: 10.1152/ajpheart.01150.2006
190. Joulin O, Petillot P, Labalette M, Lancel S, Neviere R. Cytokine profile of human septic shock serum inducing cardiomyocyte contractile dysfunction. Physiol Res. (2007) 56:291–7.
191. Wen H, Lei Y, Eun SY, Ting JP. Plexin-A4-semaphorin 3A signaling is required for Toll-like receptor- and sepsis-induced cytokine storm. J Exp Med. (2010) 207:2943–57. doi: 10.1084/jem.20101138
192. Lawes CM, Vander Hoorn S, Rodgers A, International Society of H. Global burden of blood-pressure-related disease, 2001. Lancet. (2008) 371:1513–8. doi: 10.1016/S0140-6736(08)60655-8
193. Conen D, Bamberg F. Noninvasive 24-h ambulatory blood pressure and cardiovascular disease: a systematic review and meta-analysis. J Hypertens. (2008) 26:1290–9. doi: 10.1097/HJH.0b013e3282f97854
194. Harjutsalo V, Groop PH. Epidemiology and risk factors for diabetic kidney disease. Adv Chronic Kidney Dis. (2014) 21:260–6. doi: 10.1053/j.ackd.2014.03.009
195. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies C. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. (2002) 360:1903–13. doi: 10.1016/S0140-6736(02)11911-8
196. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. (2016) 134:441–50. doi: 10.1161/CIRCULATIONAHA.115.018912
197. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. (2018) 71:1269–324. doi: 10.1161/HYP.0000000000000075
198. Small EM, Olson EN. Pervasive roles of microRNAs in cardiovascular biology. Nature. (2011) 469:336–42. doi: 10.1038/nature09783
199. Heggermont WA, Heymans S. MicroRNAs are involved in end-organ damage during hypertension. Hypertension. (2012) 60:1088–93. doi: 10.1161/HYPERTENSIONAHA.111.187104
200. Caruso P, Dunmore BJ, Schlosser K, Schoors S, Dos Santos C, Perez-Iratxeta C, et al. Identification of MicroRNA-124 as a major regulator of enhanced endothelial cell glycolysis in pulmonary arterial hypertension via PTBP1 (Polypyrimidine Tract Binding Protein) and pyruvate kinase M2. Circulation. (2017) 136:2451–67. doi: 10.1161/CIRCULATIONAHA.117.028034
201. Marketou M, Kontaraki J, Papadakis J, Kochiadakis G, Vrentzos G, Maragkoudakis S, et al. Platelet microRNAs in hypertensive patients with and without cardiovascular disease. J Hum Hypertens. (2019) 33:149–56. doi: 10.1038/s41371-018-0123-5
202. Zhang X, Wang X, Wu J, Peng J, Deng X, Shen Y, et al. The diagnostic values of circulating miRNAs for hypertension and bioinformatics analysis. Biosci Rep. (2018) 38:BSR20180525. doi: 10.1042/BSR20180525
203. Poli KA, Tofler GH, Larson MG, Evans JC, Sutherland PA, Lipinska I, et al. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Circulation. (2000) 101:264–9. doi: 10.1161/01.CIR.101.3.264
204. Spencer CG, Gurney D, Blann AD, Beevers DG, Lip GY, Ascot Steering Committee A-SCOT. Von Willebrand factor, soluble P-selectin, and target organ damage in hypertension: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Hypertension. (2002) 40:61–6. doi: 10.1161/01.HYP.0000022061.12297.2E
Keywords: cardiovascular diseases, miR-223-3p, signaling pathway, cardiomyocyte, biomarker
Citation: Zhang M-W, Shen Y-J, Shi J and Yu J-G (2021) MiR-223-3p in Cardiovascular Diseases: A Biomarker and Potential Therapeutic Target. Front. Cardiovasc. Med. 7:610561. doi: 10.3389/fcvm.2020.610561
Received: 26 September 2020; Accepted: 23 December 2020;
Published: 20 January 2021.
Edited by:
BuChun Zhang, University of Science and Technology of China, ChinaReviewed by:
Ronald J. Vagnozzi, Cincinnati Children's Hospital Medical Center, United StatesTao Li Chan, Nanjing Medical University, China
Copyright © 2021 Zhang, Shen, Shi and Yu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jian-Guang Yu, yueqingqiu@163.com; orcid.org/0000-0001-5596-5406